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Abstract 
Around thirty years ago HIV-1 was identified, and from that point the 
known epidemic has grown to over 30 million infected individuals.  Early on in the 
course of HIV-1 research, viruses were classified as either syncytia inducing, 
CXCR4-using, T-cell tropic or non-syncytia inducing, CCR5-using, macrophage 
tropic.  Since that time, several groups have shown that this is an 
oversimplification.  There is a great deal of diversity amongst CCR5-using HIV-1 
variants.  There remains a great deal to be discovered regarding HIV-1 CCR5-
tropism and how this affects other aspects of HIV-1 infection.  
The CD4 binding site (CD4bs) on the HIV-1 envelope plays a major role in 
determining the capacity of R5 viruses to infect primary macrophages.  Thus, 
envelope determinants within or proximal to the CD4bs have been shown to 
control the use of low CD4 levels on macrophages for infection.  These residues 
affect the affinity for CD4 either directly or indirectly by altering the exposure of 
CD4 contact residues.  In this thesis, a single amino acid determinant is 
described in the V1 loop that also modulates macrophage tropism.  I identified an 
E153G substitution that conferred high levels of macrophage infectivity for 
several heterologous R5 envelopes, while the reciprocal G153E substitution 
abrogated infection.  Shifts in macrophage tropism were associated with dramatic 
shifts in sensitivity to the V3 loop monoclonal antibody (MAb), 447-52D and 
soluble CD4, as well as more modest changes in sensitivity to the CD4bs MAb, 
vi 
b12.  These observations are consistent with an altered conformation or 
exposure of the V3 loop that enables the envelope to use low CD4 levels for 
infection.  The modest shifts in b12 sensitivity suggest that residue 153 impacts 
on the exposure of the CD4bs.  However, the more intense shifts in sCD4 
sensitivity suggest additional mechanisms that likely include an increased ability 
of the envelope to undergo conformational changes following binding to 
suboptimal levels of cell surface CD4.  In summary, a conserved determinant in 
the V1 loop modulates the V3 loop to prime low CD4 use and macrophage 
infection.         
In addition to determinants, this thesis seeks to evaluate the roles of 
macrophage tropic and non-macrophage tropic envelopes during the course of 
infection.  Non-macrophage tropic virus predominates in immune tissue 
throughout infection, even in individuals suffering from HIV-associated dementia 
(HAD) who are known to carry many macrophage tropic viruses.  There must be 
some advantage for these non-macrophage tropic viruses allowing them to 
persist in immune tissue throughout the disease.  This thesis demonstrates that 
there is no advantage for these viruses to directly infect CD4+ T-cells, nor is 
there an advantage for them to be preferentially transmitted by dendritic cells to 
CD4+ T-cells.  Given that transmitted/founder (T/F) viruses may preferentially 
interact with α4β7, and T/F viruses are non-macrophage tropic, I tested whether 
non-mac viruses could utilize α4β7 to their advantage.  These experiments show 
vii 
that macrophage tropism does not play a role in gp120 interactions with α4β7.  I 
evaluated whether there was a distinct disadvantage to macrophage tropic Envs, 
given their ability to infect dendritic cells and possibly stimulate the innate 
immune response.  Using infected monocyte-derived dendritic cells (MDDCs), it 
was shown that mac-tropic Envs do not generate a significant immune response.  
These experiments demonstrate that there does not appear to be any advantage 
to non-macrophage tropic Envs, and that macrophage tropic Envs are able to 
infect CD4+ T-cells more efficiently, as well as DCs.   
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CHAPTER I: INTRODUCTION  
 
1-1 Acquired Immunodeficiency Syndrome: 
 Beginning in the late 1970s and early 1980s, individuals began presenting 
to physicians with severe immunological dysfunction.  These individuals 
generally had significantly depleted CD4+ T-cells, opportunistic infections, and 
uncommon cancers.  The Center for Disease Control brought several California 
men with severe immunodeficiency to the attention of the medical community in 
the summer of 1981 [1].  Several other groups of people began presenting with 
similar immunodeficiency in addition to male homosexuals and intravenous drug 
users, including transfusion recipients, and sexual partners and children of 
individuals in the aforementioned groups.  The disease was termed acquired 
immunodeficiency syndrome (AIDS), and eventually, in 1983, Barré-Sinoussi et 
al. were able to isolate what they termed lymphadenopathy-associated virus from 
patients with acquired immunodeficiency [2].  Soon after, Gallo and others at the 
National Institutes of Health isolated a retrovirus from a patient with AIDS and 
named it human T-cell leukemia virus type III (HTLV-III), and confirmed exposure 
to the retrovirus resulted in the observed immunodeficiency [3].  Eventually, the 
virus was named Human Immunodeficiency Virus (HIV), and classified as a 
lentivirus [4].   
1-2 HIV Variability: 
2
 Soon after HIV-1 was discovered, it was shown to have extensive genetic 
variability throughout its genome, and particularly in the envelope glycoprotein, 
env, in comparison to other retroviruses.  There are several factors contributing 
to the extensive variability seen in HIV-1.  Viral DNA synthesis during reverse 
transcription is highly error prone (3x10-4 mutations per nucleotide each 
replication cycle) [5].  The frequency of recombination of the HIV genome 
associated with reverse transcription is also high [6].  This variability is 
compounded further by a high rate of viral replication in the infected host (109 
particles produced/day) [7].  As a result of this diversity, HIV-1 has extensive 
genetic phylogenetic heterogeneity.  HIV-1 has been classified into four groups, 
main (M), outlier (O), non-main and non-outlier (N), and recently group (P) 
derived from gorillas [8].  Globally, the majority of HIV-1 infections can be 
attributed to group M viruses, which can further be divided into 9 distinct clades, 
A-D, F-H, J and K [9].  In geographic areas where multiple clades are present in 
the population, circulating recombinant forms (CRFs) can be found as a result of 
the aforementioned propensity for recombination (Fig. 1-1).  The variability of the 
HIV-1 genome poses a significant challenge to the development of effective 
treatment and vaccines worldwide.  
1-3 HIV-1 Replication: 
 The HIV-1 replication cycle is generally similar to the replication of other 
retroviruses.  The process begins when the envelope glycoprotein on the virion 
3 
FIG. 1-1. Geographic distribution of HIV-1.  Most of the global HIV-1 epidemic 
can be attributed to group M virus.  The majority of infections present in North 
and South America, Australia, and Europe can be attributed to clade B viruses.  
Clade C is highly prevalent in Southern Africa and Asia.  Every clade can be 
found in Africa.  The propensity towards recombination has led to several 
circulating recombinant forms (CRF) of HIV-1.  This worldwide diversity of HIV-1 
contributes to the difficulty of combating the epidemic.   
Figure reproduced from Stebbing J and Moyle G: The Clades of HIV: Their Origins and Clinical Significance. AIDS Rev. 
2003 Oct-Dec;5(4):205-13, with permission from Permanyer Publications [9].  
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binds to CD4 on the surface of the target cell.  This triggers a conformational 
change to occur in the gp120 region of Env, exposing the co-receptor binding 
site.  Binding to a co-receptor, either CCR5 or CXCR4, both seven-
transmembrane-spanning chemokine receptors, is required to facilitate further 
conformational changes to gp41, the membrane proximal external region of Env, 
in order to allow membrane fusion to progress [10].  HIV-1 may also enter target 
cells via endocytosis [11].  Fusion of the virus, whether at the plasma membrane 
or via an endosome, releases the viral core into the cytoplasm.  The viral core is 
made up of the capsid, which encloses the viral genome, and several other HIV-1 
proteins.  This viral core associates with components of the cytoskeleton of the 
cell to move towards the nucleus [12, 13].   
 The uncoating of the capsid from the viral core reveals the reverse 
transcription complex (RTC) consisting of matrix (MA), nucleocapsid (NC), the 
viral genomic RNA, integrase (INT), reverse transcriptase (RT), and viral protein 
R (vpr) [14].  The viral genome is reverse transcribed in the RTC by RT into 
double stranded DNA, and this mature RTC is then referred to as the pre-
integration complex, which is translocated into the nucleus [15].  Integrase then 
catalyzes the integration of the HIV-1 DNA into the chromosomal DNA of the 
infected cell.  The integrated HIV DNA, now called the provirus, is then used as a 
template for RNA polymerase II directed viral RNA synthesis.  Transcription 
begins at the 5’-end of the integrated provirus and at first produces fully spliced 
mRNAs that encode Tat, Rev, and Nef [16, 17].  Tat, NF-κB, and Sp1 act along 
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with RNA pol II to produce large amounts of viral transcripts.  Rev then facilitates 
the export of unspliced and partially spliced transcripts into the cytoplasm [16].   
 Synthesis of Gag and Gag-Pol polyproteins are synthesized on 
cytoplasmic ribosomes.  Gag is made from the unspliced viral RNA, as are the 
products of the Pol gene, which are fused to the gag polyprotein due to 
translational readthrough by way of a frameshift mechanism [18].  The MA 
domain of Gag serves to direct the Gag and Gag-Pol precursor proteins to the 
plasma membrane with the help of the host’s trafficking machinery [19].  Gag 
polyproteins converge at the plasma membrane and are associated with dimers 
of genomic RNA, and begin to bud.  Translation of the gp160 Env glycoprotein 
occurs in the rough endoplasmic reticulum.  It is glycosylated and cleaved into 
mature envelope in the Golgi apparatus, and transported by vesicular trafficking 
to the plasma membrane [20].  A small fraction of the mature trimeric envelope 
glycoprotein spikes are incorporated into the budding virion.  Scission of the 
budding virion is accomplished by a sequence in the p6 domain of Gag that 
interacts with the host cell membrane budding ESCRT machinery [21].  The 
protease of the Gag-Pol precursor then becomes active during or after viral 
particle release and proteolytically processes the gag and pol proteins, resulting 
in the cone-like structure of the viral core and maturing the virus into an infectious 
virus particle (Fig. 1-2) [22].   
6FIG. 1-2. HIV-1 replication cycle. The early phase of HIV-1 replication begins with 
the recognition and binding of CD4 by gp120.  Following fusion, the viral capsid 
enters the cell and uncoats.  Reverse transcription then occurs, followed by 
nuclear import of the reverse transcribed viral genome.  The early phase of 
replication then culminates with integration.  The late phase begins with 
transcription of the proviral DNA to produce mRNAs, which are then translocated 
from the nucleus to the cytoplasm.  Translation of gag and pol occurs, and then 
the translation products move to the plasma membrane to participate in virion 
assembly.  Env is translated in the rough ER, and further process in the golgi 
before it is shuttled to the the plasma membrane for assembly.  The late phase 
ends with the budding of the virus and the maturation of the budded virion. 
Copyright license # 2872561229043 [23]  
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1-4 HIV-1 Genes:
 The HIV-1 genome is around 9.7 kB in size, and is present in the virion as 
a dimer of single stranded RNA.  It encodes structural, enzymatic, regulatory, 
and accessory proteins (Fig. 1-3).   
1-4-1 Enzymatic proteins: 
 The pol gene is downstream of Gag, and encodes three enzymes, 
protease (PR), reverse transcriptase (RT), and integrase (IN).  It is part of the 
Gag-Pol protein initially translated as Pr160gag-pol.   Inefficient ribosomal 
frameshifting during the translation of Pr55gag results in lower levels of 
expression, about five percent compared to Gag [22]. 
 Protease functions as a dimer to proteolytically cleave the polyprotein 
precursors of HIV-1 [24].  PR cleaves the gag and gag-pol polyproteins during 
the budding process, facilitating virus maturation.  This cleavage and the 
resultant morphological change are essential for the virus particle to become 
infectious.  Due to its importance for viral maturation, protease inhibitors were 
developed to inhibit the active site of the enzyme, and are a major class of drugs 
utilized clinically (saquinivir, darunivir, etc.) to treat HIV-1 patients, despite the 
emergence of escape mutations in PR to evade certain drugs.  Used in 
conjunction with other drugs, they contribute greatly to overall control of an HIV-1 
infection [25]. 
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FIG. 1-3. HIV-1 genomic organization.  The HIV-1 genome is made up of 9 genes 
that encode 15 proteins.  The schematic above is the specifically the HXB2 
genome.  The genome is flanked by long terminal repeat regions present in the 
provirus.  The structural genes are gag and env.  The enzymatic proteins are 
encoded by pol.  The regulatory proteins are tat and rev.  The accessory proteins 
are vif, vpr, vpu, and nef.  Detailed descriptions of these genes are found in the 
text.   
Figure adapted from  the HIV Los Alamos Database http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html 
  
9
Reverse transcriptase is the enzyme that gives retroviruses their name, and the 
ability to convert ssRNA into dsDNA.  RT performs three different  functions, 
minus-strand DNA synthesis directly from RNA, RNaseH activity, and plus-strand 
DNA synthesis from DNA.  The DNA polymerase activity is catalyzed by 
tRNALys3.  RT is a heterodimer of p51 and p66.  p66 contains the RNaseH 
domain [26].  As was previously mentioned, reverse transcriptase has a high rate 
of error, roughly 3x10-4 per replication cycle, exacerbated by the low affinity 
between RT and its template, that contributes to template switching during 
reverse transcription.  As a unique enzyme specific to retroviruses, RT makes a 
viable drug target.  Nucleoside analogs have been developed as chain 
terminators, such as AZT, and non-nucleoside inhibitors are directed towards a 
pocket near the active site of the p66 protein, such as nevirapine [27] 
 Integrase is the enzyme responsible for inserting the proviral DNA into the 
host cell’s DNA.  It has three domains, an N-terminal zinc-finger domain, a core 
domain, and a C-terminal domain.  Initially, IN creates 3’-recessed ends of the 
linear viral DNA as a pre-integration substrate.  Strand transfer is then 
accomplished when IN joins the 3’-recessed ends to the 5’-overhangs it creates 
in the host DNA.  DNA repair mechanisms then complete the integration process 
[28].  Similar to the other proteins derived from pol, IN has also become a target 
for antiviral drugs.  Some drugs directed towards IN function to intercalate into 
DNA, while others inhibit strand transfer, such as raltegravir [29].     
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1-4-2 Regulatory Proteins: 
 Tat, the trans-activator protein, is essential for the processivity of the RNA 
Pol II transcription complex.  It is a nuclear protein encoded by two exons.  The 
activation domain of Tat interacts with cyclin T1, which is part of the P-TEFb 
complex (cyclin T1/CDK9).  This binding induces a conformational change in Tat 
enabling efficient binding to the transactivation response region, TAR, of the HIV-
1 RNA.  The P-TEFb associated with Tat then hyperphosphorylates the RNA Pol 
II C-terminal domain, facilitating the processivity required for efficient 
transcription [30].   
 Rev, regulator of expression of virion proteins, allows the export of HIV-1 
mRNAs that possess introns or that are incompletely spliced.  Similar to Tat, it is 
encoded by two exons, and consists of two domains; an arginine rich domain that 
serves as both the RNA binding domain and the nuclear localization sequence, 
the leucine rich C-terminal domain serving as the nuclear export signal.  Rev 
binds to the rev response element, RRE, which is present in all viral RNAs, with 
the exception of tat, rev and nef fully spliced mRNAs.  Interaction with 
RanGTPase and CRM1 facilitate HIV-1 transcripts export through the nuclear 
pore [31]. 
1-4-3 Accessory Proteins: 
 The HIV-1 accessory proteins consist of Vif, virus infectivity factor, Vpu, 
viral protein u, Vpr, viral protein r, and Nef, negative factor.  These proteins were 
originally considered to be accessory proteins because they were thought to not 
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be necessary for viral replication, although recent research challenges that 
contention for some of these proteins.   
 Vif is known to interact with the host factor APOBEC3G (apolipoprotein B 
mRNA-editing enzyme, catalytic polypeptide-like 3G) and induce its degradation.  
APOBEC3G is a cytidine deaminase that is incorporated into the nascent virion 
in the absence of vif.  It causes C-to-U (ctosine to uracil) mutations during DNA 
minus strand synthesis, and causes G-to-A (guanine to adenine) hypermutation 
during reverse transcription of the HIV genome, resulting in an abortive infection.  
Vif acts through an E3 ubiqutin ligase complex to target APOBEC3G for 26S 
proteasomal degradation, thereby preventing its incorporation into virions [32]. 
 Vpu is a type-1 membrane associated protein that contributes to CD4 
downregulation and antagonizes Tetherin (BST-2 or bone marrow stromal cell 
antigen 2).  The expression of CD4 at the infected cell’s surface is detrimental to 
viral replication and spread by promoting superinfection and hampering viral 
release.   Vpu first retains CD4 in the ER, and subsequently causes the 
dislocation of CD4 back across the ER membrane where it is susceptible to 
proteasomal degradation [33].  Vpu also counteracts tetherin, which sequesters 
viral particles at the plasma membrane.  It may do this by forming complexes 
with vpu upon encountering it in the trans-Golgi network, by binding tetherin at 
the plasma membrane, by inducing ubiquitination through β–TrCP-2, and 
ultimately through proteasomal or lysosomal degradation.  The exact method of 
vpu’s antagonism of tetherin is yet to be elucidated [33]. 
12
 Vpr is thought to contribute significantly to the infection of CD4+ T-cells 
and macrophages and performs several functions.  It is incorporated into viral 
particles through an interaction with the C-terminus of the p6 domain of gag [34]. 
Vpr then facilitates the binding of the pre-integration complex (PIC) to importins 
and nucleoporins, allowing its transport into the nucleus in non-dividing cells.  Its 
interaction with the p300 transcription factor complex and the glucocorticoid 
receptor may increase HIV-1 production.  Vpr causes the phosphorylation of 
Chk1, which results in G2 cell cycle arrest [35].  These functions compound to 
contribute to better virus production.   
 Nef is another HIV-1 accessory protein with a number of functions that 
help the viral life cycle and enhance infectivity.  It also plays a role in CD4 
downregulation via a different mechanism.  Nef is myristoylated and thereby 
located at the plasma membrane, where it promotes the detachment of Lck from 
the cytoplasmic tail of CD4, and binds in its place.  AP-2 then promotes clathrin-
dependent internalization [36].  Nef also downregulates MHC class I from the 
surface of infected cells by again binding to its cytoplasmic tail and AP-1 to 
prevent normal trafficking to the plasma membrane.   In addition to 
downregulation, nef causes the activation of T-cells by phosphorylating Pak2 and 
possibly myeloid cells via Hck [37].      
1-4-4 Structural Proteins: 
 The Gag and envelope proteins are both initially expressed as 
polyproteins in the infected cell.  They are cleaved by different mechanisms 
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respectively.  The gag precursor, Pr55gag, is cleaved by PR to yield p17 matrix 
(MA), p24 capsid (CA), p7 nucleocapsid (NC), and p6 [38].    
 MA is the N-terminal portion of gag and is involved in targeting gag to the 
plasma membrane, early entry events, and the incorporation of the Env 
glycoprotein.  The major purpose of MA is directing binding and assembly of the 
viral particle at the plasma membrane.  This assembly may take place in different 
cellular compartments depending on the cell type, as is in the case of myeloid 
cells [39, 40].  The incorporation of full length Env into nascent virions is 
mediated by MA, specifically through interaction with gp41, the transmembrane 
portion of Env [38]. 
 CA forms the outer layer of the viral core, and is immediately downstream 
of MA in uncleaved gag.  It has two domains, an N-terminal core, and a C-
terminal dimerization domain.  CA is important for structural gag-gag and gag-pol 
interaction during virus formation and post-entry during the uncoating and 
initiating of reverse transcription.  The N-terminal domain also binds cyclophillin A 
(CypA).  TRIM5α is a known restriction factor against HIV-1 known to target CA 
and interfere with proper uncoating [41]. 
 NC is important for incorporating full length genomic RNA into virions and 
for gag assembly.  NC contains two zinc-finger domains, which along with the 
basic residues flanking these domains, interact with the ψ-site for encapsidation 
of the genomic RNA.  In addition to these functions, NC plays a role in 
chaperoning nucleic acids, as well as influencing proper reverse transcription and 
14
integration.  NC has also been shown to potentially play a role in plus and minus 
strand DNA transfers [42].   
 p6 is a proline rich protein on the C-terminus of gag.  It is important for 
virus release, which specifically maps to a highly conserved Pro-Thr-Ala-Pro 
(PTAP) motif near the N-terminus of p6 [43].  This protein plays a role in 
interacting with the budding machinery of the cell to facilitate virion release via 
the ESCRT-I component Tsg101.  Other late domain motifs also on p6 may 
interact with Alix, a protein important for endosomal sorting [44].  It also binds vpr 
and allows for its incorporation into virions.    
 Env is responsible for initiating infection by binding to CD4 and a co-
receptor to facilitate fusion.  It is synthesized as a precursor, gp160, which is 
eventually cleaved into gp41, the transmembrane region, and gp120, the globular 
surface protein.  As stated previously, gp160 is translated in the rough ER, where 
it is concurrently glycosylated [45].  Once in the Golgi, gp160 is cleaved by furin-
like proteases at at a highly conserved K/R-X-K/R-R motif into mature gp120 and 
gp41 proteins [46].  The Env proteins then form heterotrimers that are trafficked 
to the plasma membrane, where they will be incorporated into virions or 
endocytosed.   
 About half of the total mass of gp120 is made up of glycans, which 
function to shield Env from the host immune machinery, aid virion binding the 
surface of target cells, and contribute to the overall structure of Env [47].  gp120 
has five variable domains and five constant regions.  There are a number of 
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conserved cysteines that impart tertiary structure and delineate the different 
variable domains.  Variable domain 1, (V1), and V2 are variable loops within the 
context of a larger loop via disulfide bonds, and are the most variable regions of 
the envelope [48].  
 Gp120 is made up of a highly glycosylated outer domain composed of a 
double β-barrel, and an inner domain consisting of a 3-helix, 4-strand bundle 
along with a 7-stranded β-sandwich.  There is also a 4-strand bridging sheet that 
is composed of two strands from the inner domain (β2-β3) and two strands from 
the outer domain (β20-β21) [49].  The CD4 binding site is formed by the folding of 
different conserved regions of gp120 into a conformation receptive to CD4, 
specifically in C1, C3, and C4 [50].  CD4 binds in a depression between the inner 
and outer domains and the bridging sheet.  It is the binding of CD4 that catalyzes 
the conformational change that forms the bridging sheet.  This conformational 
change entails a change in orientation of the α1 helix from the inner domain and 
the significant movement of the β2-β3 strands from the inner domain around 40 Å 
to a closely adjacent postion to β20-β21 (Fig. 1-4, A) [51].  CD4 binding also 
induces changes in V1/V2 and V3, exposing epitopes not accessible in the 
unliganded form.  Co-receptor binding via CCR5 or CXCR4 is facilitated by the 
CD4-bound gp120.  The V3 loop is known to be of particular importance in 
contributing to membrane fusion and determining co-receptor specificity [52-54].  
In addition to the V3 loop, the bridging sheet is also known to play a role in co-
receptor usage [55].    
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FIG. 1-4. HIV-1 Envelope Structure.  (A) The structure of the unliganded gp120 of SIV 
has been resolved, and here it shows the inner domain in yellow and the outer domain in 
green.  The portions of the bridging sheet are in purple.  The drastic conformational 
change between the unbound SIV and the CD4-bound structure of gp120 of the bridging 
sheet is caused by the binding of CD4. (B) An electron tomographic structure of the 
native unbound HIV-1 envelope trimer.  (C) The conformational change of the overall 
trimeric glycoprotein spike upon binding CD4 is shown. The trimer opens, moving V1/V2 
loops away from the center of the trimer.  On top are electron density maps top view 
fitted with gp120 structures, with V1/V2 in red. In the model on the bottom the yellow 
circle represents the CD4 binding site in the unbound trimer, and the green circle is the 
V3 loop after conformational rearragement subsequent to CD4 binding.  CD4 is in 
yellow, gp120 is in red/purple, and gp41 is in blue.     Figure adapted with permission from  Da LT et 
al. J Phys Chem B. 2009 Oct 29;113(43):14536-43 [51]. Copyright year 2009 American Chemical Society; and Copyright 
license # 2881940918046,[56] and White TA et al. J Virol. 2011 Dec;85(23):12114-23 [57] 
A B 
C 
CD4 
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 gp41 is responsible for fusing the viral membrane with the host cell’s 
plasma membrane.  It is comprised of an extracellular domain, a transmembrane 
domain, and a cytoplasmic tail.  The extracellular domain is composed of the 
fusion peptide, which is the N-terminal hydrophobic region, a polar region, HR1 
and HR2, which are coiled-coil heptad repeat regions, and the membrane 
proximal external region (MPER), which is Trp-rich [58].  When CD4 binds 
gp120, it causes a conformational change in gp41 that exends the fusion peptide, 
which then inserts into the target cell membrane.  The HR motifs from the trimer 
fold over one another in an antiparallel manner to form the six-helix bundle 
responsible for bringing the membranes close enough to initiate fusion [59].  The 
cytoplasmic tail of gp41 is involved in Env incorporation into virions, gp120 
shedding, and the expression of Env at the cell surface.  A Y-X-X-L motif in the 
CT directs clathrin-mediated endocytosis of Env via adaptor protein complex 2 
(AP-2) [60].  gp41 plays a significant role in overall Env structure and function.  
 Crystal structures of HIV-1 monomeric gp120 have been resolved.  
However they represent the conformation in the CD4 bound form and not the 
unliganded structure present in the native trimer.  There is currently no crystal 
structure of the native trimer, although a high resolution electron tomographic 
structure of the unliganded, uncleaved trimer was presented this year (J. 
Sodroski, CROI 2012).  There are also several lower resolution electron 
tomographic structures of the trimer, including an unliganded form and forms 
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bound to sCD4 (Fig. 1-4, B & C) [56].  The unbound trimer shows distinct gp120 
subunits with the variable loops V1/V2 and V3 near the apex.  Upon binding of 
CD4, the gp120 subunits move further apart, and the V1/V2 loops swing laterally, 
with the V1/V2 loops and the CD4 binding site moving away from the center of 
the trimer (Fig. 1-4 C).  There also appears to be gp41 conformational changes.  
In the unbound state, taking the many glycans into consideration, the CD4 
binding site seems to be the only portion of the trimer significantly accessible 
[61].   
    
1-5 HIV-1 Pathogenesis: 
 HIV-1 is known to infect CD4+ cells resulting in their death and the virus’ 
propagation, but this is an oversimplification of what occurs in the host 
throughout the course of the infection.  The course of HIV-1 infection can be 
divided into three distinct stages of infection, acute, chronic, and late-stage or 
AIDS.  The time period shortly after the host is infected and prior to the adaptive 
immune response is referred to as the acute phase of infection.  CD4+ effector T-
cells in the gut and associated lymphatic tissue are severely depleted [62].  A 
significant portion of these cells express CCR5, the co-receptor predominantly 
used by transmitted virus.  This accompanies flu-like symptoms and a large spike 
in plasma HIV-1 RNA titers in plasma (up to 107 copies/mL).  This phase of high 
viral replication quickly declines in several weeks to a steady state level, termed 
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the viral set point [63]. During the acute phase, HIV-1’s ability to evade the innate 
immune response allows it to burgeon in the host and establish the infection.   
 Following the resolution of acute infection, which coincides with the 
detection of HIV-1 specific cytotoxic T lymphocytes (CTLs) [64, 65], a chronic 
phase begins where most infected individuals are relatively asymptomatic.  It is 
during this phase that the number of CD4+ T-cells detected in blood gradually 
declines, although throughout this latent phase of infection, individuals are 
generally able to mount an immune response to other infections.  The virus is 
most likely infecting many CD4+ T-cells, and large amounts of these cells are 
likely turning over, and this many eventually leads to immune exhaustion due to 
chronic activation and inflammation [66, 67].  The adaptive immune response is 
able to robustly generate antibodies to the virus.  However, this adaptive 
response is usually unable to cope with the diversity of the virus or penetrate all 
of the tissue reservoirs in vivo [68].   
 During late-stage disease, or AIDS, plasma viremia increases and CD4+ 
T-cells decline even further.  Without treatment, individuals are unable to mount 
an effective cellular immune response when their CD4+ T-cell count drops below 
200 cells/mm3 [69].  Eventually, without treatment, the individual will succumb to 
opportunistic infections. A co-receptor switch can occur during this late disease 
stage from CCR5 using to CXCR4 using virus.  The availability of CCR5+ target 
cells may be significantly depleted.  The co-receptor switch allows CCR5- 
CXCR4+ CD4+ T-cells, naïve cells, to be colonized and is often associated with 
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faster disease progression [70, 71].  Once an individual reaches this late stage 
disease, they will most likely succumb to the disease in a short period of time 
without treatment.  The main form of treatment is currently highly active 
antiretroviral therapy (HAART), which is a generally accepted combinatorial 
approach to utilize different classes of antiretroviral drugs to address the 
pathogenic effects of HIV infection [72].   
 Numerous factors influence immunopathogenesis.  Innate immunity plays 
an important role in combating HIV infection, and the HIV-1 virus has a number 
of methods of subverting the innate immune response as a result.  The activation 
of immune cells by HIV-1 leads to IFN-α production, which in turn leads to the 
up-regulation of a number of cellular restriction factors, such as APOBEC3G and 
SAMHD1 [73-75].  Activation of the host factor Trex1 helps to prevent innate 
signaling in response to HIV nucleic acids [76].  Acute infection by HIV-1 also 
promotes NK-cell expansion and activation, which in turn leads to better control 
over disease progression by the host [77-79].    
Cellular responses to HIV infection contribute significantly to 
pathogenesis.  Certain individuals, referred to as elite controllers or elite 
supressors, are able to successfully control viral replication for extended periods 
of time, as well as not showing other signs of disease progression [80].  The 
CD4+ T-cells of these individuals proliferate in response to infection and secrete 
multiple cytokines, similar to non-pathogenic infections seen in primates.  
Chronic progressors, however, lack this CD4+ T-cell proliferation, and only 
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secrete IFN-γ [81].  The CD8+ T-cells of these elite controllers also appear to 
contribute greatly to their ability to control disease progression by secreting 
multiple cytokines and exhibiting more efficient proliferation and killing of infected 
cells, whereas these characteristics are not observed in chronic progressors [81].  
Cellular immunity to HIV infection is therefore an important factor contributing to 
overall pathogenesis.    
Antibodies also play a role in HIV-1 pathogenesis, both neutralizing and 
non-neutralizing.  Neutralizing antibodies arise several weeks after infection upon 
activation of the adaptive immune response to HIV [82].  Broadly neutralizing 
antibodies generally arise after a much longer period of infection, potentially 
needing chronic antigen exposure, higher plasma viral loads, and increased 
affinity maturation [81].  Non-neutralizing antibodies can facilitate immune 
recognition by binding HIV-1 antigen, and recruiting immune cells via their Fc 
fragment, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) or 
antibody-dependent cell-mediated virus inhibition (ADCVI) [83].    
1-6 HIV-1 Tropism: 
 The term “macrophage tropism” was first used early on in the course of 
HIV research.  Two distinct groups of HIV-1 isolates were described.  One group 
was capable of efficiently infecting and inducing syncytia in T-cell lines and T-cell 
cultures, and was termed T-tropic.  A second group was capable of infecting 
primary macrophage cultures, did not induce syncytium formation in T-cell 
cultures, and was termed mac-tropic or M-tropic [84, 85].  CXCR4 was eventually 
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identified as the co-receptor for the T-tropic, syncytium-inducing viruses, and 
CCR5 was identified as the co-receptor for M-tropic, non-syncytium inducing 
viruses [86].  It has since been shown that in infected patients, HIV-1 can utilize 
CCR5, CXCR4, or both, (now described as R5, X4, or R5X4 viruses) and that 
ascribing M and T tropism to the viruses exclusively on their usage of a specific 
co-receptor is an over-simplification [87, 88]. 
 There is significant variation amongst R5 using viruses.  As early as 1987, 
R5 isolates were found within the same individual that differed significantly in 
their ability to infect macrophages.  JR-FL and JR-CSF, both used in these 
studies, were isolated from brain and cerebrospinal fluid respectively [89].  There 
have since been a number of primary isolates identified that differ drastically in 
their ability to infect macrophages, but still use R5 as their primary co-receptor 
[90-92].   
CCR5 is the main coreceptor for transmitted HIV-1 [93], [10], while 
CXCR4-using variants become detectable in up to around 50% of AIDS patients 
and are associated with a rapid decline in CD4+ T cells, leading to death [94].  It 
has also been shown that R5 using isolates can vary in their ability to infect 
target cells expressing low levels of CCR5 [95, 96].  R5 isolates obtained from 
brain tissue display a greater incidence of macrophage tropism, or an ability to 
infect macrophages, than do isolates from the blood and immune tissue [91, 96-
98].  There is also evidence that macrophage tropic isolates are more prevalent 
in late stage disease or AIDS [99-101].  The ability of R5 viruses to infect 
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macrophages correlates with an ability to infect cells expressing low levels of 
CD4 [102] and to sensitivity to inhibition by reagents specifically targeting the 
CD4-gp120 interaction [97, 103].  This indicates that Env is a major determinant 
of macrophage tropism.  
 There are several Env determinants that have been identified that affect 
the macrophage tropism of envs, and accordingly some of these are found in or 
around the CD4 binding site.  An asparagine at position 283, within the CD4 
binding site within C2, was identified as conferring macrophage infectivity in 
certain Envs [104].  Further determinants were mapped to regions flanking the 
CD4 binding site, reinforcing the fact that residues affecting the CD4 binding of 
gp120 are responsible for macrophage tropism [105].  Residues outside and 
apart from the CD4 binding loop have also been found to influence macrophage 
tropism, such as residues within the V3 loop, and an N-linked glycosylation at 
position 386 of the V4 loop [105, 106].  While these residues and glycans are 
distinct from the CD4 binding site, they may still play a role in the gp120-CD4 
interaction by altering accessibility or conformation, seen by their effects on b12 
sensitivity, a broadly neutralizing monoclonal antibody directed against an 
epitope overlapping the CD4 binding site [107].  In addition to specific 
determinants, recent work has shown that late-stage disease mac-tropic Env 
possess lower gp120 charges, while non-mac tropic Envs in immune tissue have 
a more positive gp120 charge [108].   
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 The effect of macrophage tropism on HIV-1 in the context of the infection 
can be significant.  Viruses that interact more efficiently with CD4 and are able to 
use low levels of CD4 may confer more efficient infection of all CD4+ cells, 
including T-cells.  The emergence of macrophage tropic variants could contribute 
to the late stage loss of CD4+ T-cells, acting to exacerbate the overall T-cell 
decline [99, 101].  During the course of disease progression, the gradual loss of 
central memory T-cells is observed.  These cells express significantly lower 
levels of CCR5, and are generally less susceptible to infection by R5-tropic 
viruses [109].  It may be possible that viruses emerge during the chronic stage 
that are able to exploit these lower levels of CCR5.  Consistent with this, one 
group reported a greater tolerance for variability in the N-terminus of CCR5 by 
macrophage tropic envelopes [110], while another study finds that mac-tropic 
envelopes more efficiently use low levels of CCR5 [111].     
Macrophage tropic Env can frequently be detected in patients suffering 
from neurological effects of HIV-1 infection.  Virus can be detected in brain tissue 
early after infection, but significant macrophage infiltration into neurological tissue 
occurs in the later stages of disease [112].  In late stage disease, CD16+ 
monocytes expand, become activated, and have the propensity to traffick across 
the blood-brain barrier [113, 114].  Some of the macrophages that traffic into the 
brain may be infected, which has been seen in the case of SIV [115].  The 
infection of macrophages in the brain, and their contribution to inflammation most 
likely contributes to dementia in HIV patients. 
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Mac-tropism does not seem to play an important role in the initial 
transmission of HIV-1.  It has recently been shown that the majority of mucosal 
transmission events are the result of a single virus, referred to as a transmitted 
founder virus (T/F) [116, 117].  Several studies have been conducted on T/F 
viruses from clade B [118] and clade C [117, 119] demonstrating that they 
generally do not infect macrophages well.  There have been very few T/F viruses 
characterized, so these observations will need to be verified using additional T/F 
viruses.   
1-7 Myeloid Dendritic Cells and HIV-1: 
   There are two major types of dendritic cells, myeloid (mDC) and 
plasmacytoid (pDC).  Langerhans cells are also a type of dendritic cell found in 
the dermis.  The mDCs bridge the innate and adaptive immune responses, and 
play a significant role in antigen presentation.  They are readily found in immune 
and mucosal tissue and are one of the first cell types to encounter HIV during 
transmission [120].  Both immature and mature mDCs are susceptible to infection 
by HIV-1 [121-123].  These mDCs are known to express CD4, CCR5, and 
CXCR4, although they express these receptors at relatively low levels [124-126].  
R5-tropic virus infects mDCs significantly better than X4-tropic virus, possibly due 
to a generally higher level of CCR5 expression on these cells compared to 
CXCR4 [121].  HIV-1 replication in mDCs is generally significantly less than what 
is observed in CD4+ T-cells, probably due to several factors, including low levels 
of receptor and co-receptor, significant degradation of internalized HIV in 
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endosomal compartments [110], and the expression of host restriction factors, 
such as SAMHD1. 
 Due to the small amount of mDCs able to be isolated from donors, 
monocyte-derived dendritic cells (MDDCs) are often used in vitro to study DC 
interactions with HIV.  Monocytes isolated from peripheral blood differentiate into 
MDDCs after being stimulated in culture by IL-4 and granulocyte-macrophage 
colony stimulating factor (GM-CSF) [127].  Similar to myeloid DCs, they express 
CD11c, MHC class II molecules, and c-type lectin receptors such as DC specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) [128].  They 
may bind HIV virions more through C-type lectins than through CD4 [126].  
MDDCs, however, do not completely recapitulate DC subsets found in vivo. 
 mDCs and MDDCs both efficiently transmit HIV-1 to CD4+ T-cells.  They 
are able to bind HIV-1 via several receptors including DC-SIGN, langerin, 
mannose receptor, CD4, and others [129].  After binding virus, immature 
dendritic cells traffic to lymphoid tissues, where they mature and stimulate naïve 
T-cells via MHC class II antigen presentation [130].  Chemotaxis to lymphoid 
tissue brings DCs carrying HIV into contact with CD4+ T-cells, facilitating trans-
infection of T-cells.  Mature DCs transfer virus to target cells more efficiently than 
immature DCs [123] via an infectious synapse, a junction formed between DCs 
and T-cells.  In addition to transmitting virus via the infectious synapse, DCs can 
also take up virus into endosomes, and facilitate trans-infection via these cellular 
compartments [131].  mDCs can also transfer virus in cis, presenting de novo 
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virus to target cells for infection, despite the low incidence of direct infection 
[132].    
1-8 Scope of Thesis 
 The findings presented in this thesis demonstrate that position 153 in the 
V1 loop modulates macrophage tropism in several primary isolates.  In several 
clades, a glutamate at position 153 (E153) is well conserved.  It was observed 
that a glycine at the same position facilitated greater macrophage tropism, and 
that by changing this residue to a glutamate (G153E), this ability to infect 
macrophages was abrogated.  When the reverse change was made, E153G, this 
substitution was able to impart an ability to infect macrophages.  It will be 
demonstrated that these changes to position 153 cause shifts in sensitivity to the 
V3 MAb 447-52D and soluble CD4, while only modestly affecting sensitivity to 
the broadly neutralizing antibody b12.  These changes in sensitivity indicate that 
these substitutions at position 153 cause a rearrangement of the V3 loop that 
allows low CD4 usage.  The significant changes in sensitivity to sCD4 and 
minimal changes in sensitivity to b12 further indicate that residue 153 confers an 
increased ability for gp120 to undergo conformational changes after initially 
interacting with CD4.   
 In addition to individual determinants, data presented in this thesis 
demonstrate that R5 non-macrophage tropic envelopes do not confer an 
enhanced tropism for CD4+ T-cells.  Using a panel of envelopes from nine 
patients, data will demonstrate that envelopes that are able to exploit the low 
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levels of CD4 on macrophages are also able to do the same on dendritic cells, 
although less efficiently.  Non-macrophage tropic envelopes predominate in 
immune tissue, yet these non-mac tropic envelopes are unable to infect CD4+ T-
cells directly as well as the mac-tropic Envs.  In the context of DCs transmitting 
these non-mac tropic isolates, they have no advantage over mac-tropic 
envelopes.  With respect to tropism and stimulation of an immune response, 
there does not appear to be any advantage to non-mac tropic Envs despite their 
prevalence throughout the course of disease.  These findings help to further 
elucidate the role of mac-tropic and non-mac tropic Envs in the context of HIV-1 
infection.   
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CHAPTER II: MATERIALS AND METHODS 
 
2-1 Patient envelopes:  
HIV-1 clade B envelopes amplified from pediatric subject 
P1114, as well as NA118 LN27, NA420 LN40, NA20 LN8, and JRCSF, have 
been described previously [89, 91, 98]. The non-macrophage-tropic LN40 
envelope was chimeric carrying the gp41 sequence of NA420 B33 to confer 
optimal infectivity [91, 98]. The Indian clade C envelope, 25925-2, was obtained 
from the NIH AIDS Research and Reference Reagent Program [133]. The clade 
D envelope, CMT19 S531, was amplified from a Cameroon semen sample, 
whereas the clade B envelope, FL5-2-209 was amplified from a frontal lobe 
autopsy sample of an AIDS patient with HIV-associated dementia that was 
obtained from the National NeuroAIDS Tissue Consortium. Envelopes derived 
from patients 7766, 10017, 6568, and CA110 were also obtained from tissue 
obtained from the National NeuroAIDS Tissue Consortium (refer to table 4-1).  
Patient 43 Envs were amplified from the blood and semen of an adult patient 
[98].  All transmitted/founder viruses used were obtained from the NIH AIDS 
Research and Reference Reagent Program [116].  Envs described herein as 
macrophage tropic are those envelopes better able to exploit low levels of CD4 
on the target cell for infection.  Envelopes were expressed from pSVIIIenv or 
from pcDNA3.1TOPO for the production of pseudovirions. 
2-2 Cell cultures:  
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293T cells were used to prepare Env-containing (Env+) pseudovirions by 
transfection.  Env+ pseudovirions were titered on HeLa TZM-bl cells, which were 
also used for HIV-1 neutralizations.  HeLa TZM-bl cells express high levels of 
CD4 and CCR5, and possess β-galactosidase and luciferase reporter genes 
under the control of the HIV long terminal repeat [134].  293T and HeLa TZM-bl 
cells were cultured in Dulbecco modified Eagle medium (DMEM) with 4% fetal 
bovine serum (FBS) and gentamicin (10µg/mL).  
Primary macrophages and monocyte derived dendritic cells (MDDCs) 
were prepared from elutriated monocytes (provided by the University of 
Massachusetts Medical School Center for AIDS Research) or by adherence from 
buffy coats.  Briefly, 0.5 ml of elutriated monocytes (5x105/ml) was plated in each 
well of 48-well cell culture dishes and cultured in 10% human plasma in DMEM 
for 5 to 7 days before infection.   
Alternatively, 5x107 peripheral blood mononuclear cells (PBMC) from a 
buffy coat (Research Blood Components LLC, Brighton, MA) were plated into 14-
cm bacterial culture dishes for 3 h before extensively washing away nonadherent 
cells, culturing overnight, and repeating the washes. The adhered monocytes 
were then cultured for 5 to 7 days in 10% human plasma in DMEM before 
treatment with EDTA and transfer to 48-well tissue culture dishes the day prior to 
infection [92].  MDDCs were obtained from adhered monocytes by culturing in 
XVIVO15 media (Lonzo) with 100ng/mL granulocyte-macrophage colony 
stimulating factor (GMC-SF) and 40ng/mL IL-4 (Peprotech) for 5-7 days in 75ml 
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cell-culture flasks [127].  MDDCs were scraped from the flask for use in assays 
after incubating with EDTA for 7 minutes at 37°C.     
Primary PBMCs were isolated from whole human blood or buffy coats by 
Ficoll- Paque separation.  Red blood cells were lysed with an Ammonium 
Chloride solution, and cells were then washed twice with sterile PBS and cultured 
in Roswell Park Memorial Institute 1640 medium (RPMI) with 10% fetal bovine 
serum and IL-2 (5ng/mL, Roche Inc.).  PBMCs were stimulated with 5 µg/ml 
Phytohemagglutinin.  CD4+ T-cells were isolated from stimulated PBMCs using 
Stem Cell negative selection for CD4+ T-cells.   
CD4+ T-cells used in the α4β7 experimentation were derived from PBMCs 
cultured in 10% RPMI, and activated with the OKT3 MAb to CD3 (1 µg/ml) 
(eBioscience), IL-2 (20 IU/ml) (Roche), and retinoic acid (10 nM) (Sigma Inc.).  
CD4+ T-cells were negatively selected, washed with PBS, and stained with an 
anti-human β7 antibody (eBioscience) at 4°C for 1 hr.  They were then washed 
with PBS and sorted into β7+ and β7- populations using a BD FACSAria.  Prior to 
use in any assays, they were cultured overnight post-sorting in 10% RPMI, IL-2, 
and retinoic acid (the same concentrations).      
Jurkat E6-1 cells stably express integrin α4 [135].  Jurkat E6-1 cells stably 
transfected with either pCXbst-CCR5, or pCXbst-CCR5 and pCX4pur-ITGB7c 
were obtained from H. Gottlinger.  They were cultured in 10% FBS RPMI with 
0.5 µg/ml puromycin (driving expression of integrin β7) and 5 µg/ml blasticidin 
(driving expression of CCR5).   
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2-3 Preparation of Env+ pseudovirions and Replication Competent Virus:  
Portions (1.25 µg) of pSVIIIenv or pcDNA3.1TOPO plasmids carrying 
complete env sequences were cotransfected by using calcium phosphate into 
293T cells (Profection mammalian transfection kit, Promega), together with 1.25 
µg of pNL43 that carried a premature stop codon in the envelope (Env+) [105, 
107].  In the case of GFP reporter Env+ pseudovirions, the pHIvec2.GFP [136] 
vector was also transfected at a ratio of 2:1:1 to the pNL4.3 env- and the 
envelope carrying vector.  Media (4% FBS DMEM) was changed 8-18 hrs post-
transfection.  Pseudovirions were harvested 48 h post-transfection, clarified by 
low-speed centrifugation, aliquoted into 0.5-ml portions, and snap-frozen in liquid 
nitrogen.  3 µg of DNA for each infectious clone was transfected into 293T cells 
using the same method described above, along with 1.25 µg VSV-G.    
2-4 Infectivity assays:  
Infectivity assays were carried out as described previously [105, 107].  
Primary macrophages were treated with 100 µl of DEAE dextran (10 µg/ml) prior 
to infection before adding an equal volume of serially diluted Env+ pseudovirions 
and spinoculation for 30 min in a benchtop centrifuge [137]. Growth medium 
containing 10% human plasma was then added.  After 7 days of incubation, the 
macrophages were fixed in cold methanol-acetone (1:1), washed, and 
immunostained for p24 with the MAbs 38:96K and EF7 (UK Centre for AIDS 
Research), followed by an anti-mouse IgG-β-galactosidase conjugate and X-Gal 
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) substrate (0.5mg of X-
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Gal/ml, 3 mM potassium ferricyanide, 3 mM potassium ferricyanide, 1mM 
magnesium chloride). DEAE dextran and spinoculation enhance virus infectivity 
by ~20-fold by increasing attachment [137]. Infection according to this procedure 
does not bypass the requirement of CD4 and CCR5 for infection, which thus 
remains sensitive to entry inhibitors. Thus, macrophage infection conferred by 
envelopes described here was completely inhibited by maraviroc (data not 
shown).  HeLa TZM-BL cells were plated at 0.5 ml per well (5x105 cells/ml) in 48-
well dishes the day prior to infection and infected.  After 72 h, the HeLa TZM-BL 
cells were fixed in 0.5% glutaraldehyde in phosphate-buffered saline, and β-
galactosidase–X-Gal substrate was added. 
Infected macrophages and HeLa TZM-BL cells stain blue for β-
galactosidase.  This β –gal expression is driven by the HIV-1 LTR promoter in 
TZM-BLs, and is thereby dependent upon Tat expression [138].  Since Env+ 
pseudovirions are only capable of a single round of infection, stained infected 
cells are recorded as focus-forming units (FFU).  The macrophage infectivity data 
presented were derived from FFU values averaged from two experiments using 
cells from different donors.  Envs are determined to be macrophage tropic if they 
are able to exploit the low levels of CD4 on macrophages for infection.  This is a 
qualitative determination.   
 PBMCs and CD4+ T-cells were infected with GFP reporter Env+ 
pseudovirus by titrating the virus on the cells in a 96-well plate (130,000 
cells/well).  100 µL of viral supernatant was added to each well, serially diluted, 
34
and infection was quantified 2 days post infection by counting GFP-positive cells 
using a fluorescent microscope.  Jurkat E6-1 cells and β7 sorted CD4+ T-cells 
were infected in the same manner.   
2-5 Trans infection assay:  
Autologous PBMCs/CD4+ T-cells and MDDCs were derived from whole 
blood or a buffy coat.  After MDDCs were cultured as described, they were 
treated with EDTA, scraped, and aliquoted into 96-well PCR plate (90,000 
cells/well).  100 µL of viral supernatant was added, and cells were incubated for 1 
hr at 37°C.  Cells were then washed twice with PBS, and co-cultured with 
autologous PBMCs/CD4+ T-cells, which were cultured as described previously.  
Infectivity was quantified 2 days post infection by counting GFP+ cells.  Only 
PBMCs/CD4+ T-cells were counted, as infected MDDCs do not express the GFP 
reporter gene until 3 days post infection.      
2-6 Inhibition and neutralization assays:  
Inhibition and neutralization assays were carried out as described 
previously using HeLa TZM-BL cells as target cells [97, 105, 107].  Neutralization 
was measured as a reduction in β-galactosidase reporter gene expression after 
infection of HeLa TZM-BL cells with MAb-treated pseudovirions.  200 µL of HeLa 
TZM-BL (5×104 cells/ml) was added to each well in 96-well luminescence plates 
(Corning Inc.) 1 day prior to neutralization assays.  200 FFU of pseudovirions 
was incubated with twofold dilutions of the respective inhibitor or antibody for 2 
hrs at 37°C.  50 µL of this mixture was incubated with HeLa TZM-BL cells at 
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37°C overnight before being removed, and 200 µL of 4% DMEM was added. 
Seventy-two hours after incubation the residual infectivity was estimated by 
measuring the β-galactosidase activity using a luminescent readout.  The 
luminescence reaction was initiated by first removing the medium in each well 
and adding 100 µL of Beta-Glo (Promega Inc.) with 100 µL of DMEM (no phenol 
red) per well.  Luminescence was measured 30 min later.  
2-7 Analysis of V1 loop phylogeny:  
HIV-1 V1 loop sequences were downloaded from the HIV sequence 
database at Los Alamos and aligned by using CLUSTAL W2, and the 
frequencies of different amino acids at residue 153 were evaluated. 
2-8 Immunostaining for Fluorescent Microscopy:  
MDDCs were washed once with PBS, and then incubated with respective 
antibodies from BD Biosciences for 1 hr at 37°C.  Cells were then washed with 
PBS, and placed in 10% FBS-RPMI media.  CD11c staining was imaged using 
the appropriate phycoerythrin filter.   
2-9 ELISAs: 
HIV-1 gp120 ELISA kit (Advanced Bioscience Laboratories inc.) was used 
on HIV-1 viral supernatant to quantify gp120 levels.  p24 ELISA kit (Advanced 
Bioscience Laboratories Inc.) was used to quantify amount of virus captured by 
MDDCs.  MDDCs were incubated with viral supernatant for 1 hr, washed twice 
with PBS and lysed in the provided disruption buffer.  This lysate was used in the 
p24 ELISA.  The IFNα ELISA kit (Mabtech Inc.) was used to quantify IFNα in the 
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supernatant of the infected MDDCs four days post infection. 
2-10 Flow Cytometry Analysis:  
Uninfected MDDCs were treated with Versene, scraped, and washed with 
2% PBS 7 days after isolation from blood.  All antibodies used were incubated 
with cells for 1 hr at 4°C, then washed with PBS, and analyzed on a BD 
FACSCalibur.  7-AAD was used to gate on live cells, and all compensation was 
performed using Flowjo (Tree Star, Inc.).   
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CHAPTER III: A CONSERVED DETERMINANT IN THE V1 LOOP 
OF HIV-1 MODULATES THE V3 LOOP TO PRIME LOW CD4 USE 
AND MACROPHAGE INFECTION 
 
3-1 Introduction: 
  HIV-1 fusion and entry into cells is triggered by sequential interactions 
between the viral envelope glycoprotein with CD4 and a seven-transmembrane 
coreceptor. HIV-1 R5 viruses efficiently infect primary CD4+ memory T cells that 
express CCR5.  However, as was previously described, these viruses confer 
widely divergent abilities to infect primary macrophages [90, 91, 96-98].  In 
contrast, many envelopes from immune tissue such as lymph nodes, infected 
macrophages very inefficiently [98]. Macrophage infectivity correlated with the 
capacity to infect indicator cell lines via low levels of CD4 [91, 96, 98, 139], an 
observation that reflects the lower expression of CD4 on macrophages compared 
to T cells [140-142]. Consistent with this observation, envelope determinants that 
control macrophage tropism have been mapped to residues within or proximal to 
the CD4 binding site [98, 104, 105]. Thus, Dunfee et al. reported that an 
asparagine at residue 283 in the C2 part of the CD4bs was associated with brain 
envelopes and HIV-associated dementia [104]. N283 also conferred increased 
levels of macrophage infectivity when introduced into R5 envelopes where 
residue 283 is usually T or I [104, 105]. N283 was reported to confer an 
increased affinity of gp120 for CD4, probably because the asparagine may 
facilitate the formation of a hydrogen bond with Q40 on CD4 [104]. Nevertheless, 
N283 only partially associates with macrophage infectivity.  Other envelope 
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determinants that likely affect exposure of CD4 contact residues have also been 
identified [105], and non-macrophage tropic envelopes possessing N283 have 
also been amplified form immune tissue [91, 98, 108].  Determinants on the 
flanks of the CD4 binding loop were identified, which probably modulate 
exposure of the adjacent and conserved CD4 contact residues. The CD4 binding 
loop is likely to be the main part of the CD4bs that is exposed on the native 
envelope trimer and an early contact for CD4 [143]. Of note, the identified CD4 
binding loop flank residues also shifted sensitivity to the glycan-specific 
monoclonal antibody (MAb), 2G12, indicating that movement of proximal glycans 
could be one mechanism involved in the exposure of CD4 contact residues [144].  
The CD4 binding site is also a major target for vaccine development 
aimed at eliciting neutralizing antibodies [145]. It is therefore important to fully 
understand how this site is exposed or protected during viral evolution and how 
this affects tropism, neutralization sensitivity, and other envelope properties.  
Here, closely related HIV-1 envelopes from a pediatric subject in late disease are 
described that differ profoundly in their capacity to infect primary macrophages.  
A single amino acid determinant in the V1 loop is identified that confers dramatic 
shifts in macrophage tropism, as well as affecting sensitivity to the V3 loop MAb, 
447-52D, sCD4, and the CD4bs MAb, b12.  These data are consistent with a 
model where the V1 determinant controls the conformation or exposure of the V3 
loop, which in turn primes the envelope for low CD4 use and macrophage 
infection. 
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3-2 HIV-1 envelopes amplified from the plasma of a pediatric HIV-1 subject vary 
in their capacities to confer macrophage infection: 
Several HIV-1 envelopes were previously described that had been 
amplified by PCR from the plasma of a pediatric AIDS patient, P1114 [98]. These 
envelopes were amplified when the patient was asymptomatic in the A2 stage of 
disease (in 1995 to 1996), as well as after the patient had progressed to 
symptomatic disease in C3 (in 1998) using the CDC categories (http://www.aids-
ed.org/aidsetc?page_cm-105_disease). Single round pseudovirions carrying 
each envelope were titrated in infectivity assays on HeLa TZM-BL cells and 
monocyte-derived macrophages. All of the Envs conferred high infectivity titers 
on HeLa TZM-BL cells, which express high levels of CD4 and CCR5. However, 
only two Envs from the C3 stage of infection (C98-15 and C98-18) conferred 
significant infection of primary macrophages (Fig. 3-1). 
3-3 Specific envelope residues in the V1V2 loops that segregate with 
macrophage infectivity:  
The five envelopes from the C3 stage of infection were very closely 
related in sequence. Two distinct amino acid changes in the V1V2 loops were the 
only differences over the entire gp160 sequence that segregated with 
macrophage infectivity (Fig. 3-2). Figure 3-3 shows a sequence alignment for the 
V1V2 loops of these envelopes. Env 98-15 is the most macrophage-tropic 
envelope and carries E153G and D167N substitutions in V1 and V2, respectively. 
40
 
FIG. 3-1. Macrophage tropic R5 viruses detected in late-stage disease of a 
pediatric AIDS patient. R5 envelopes were amplified from three plasma samples 
of a pediatric AIDS patient P1114 in 1995, 1996 (disease stage A2), and 1998 
(disease stage C3). Single-round Env pseudovirions were prepared and used to 
infect HeLa TZM-BL cells and monocyte-derived macrophages. All envelopes 
exhibited high infectivity titers on TZM-BL cells. Two of the envelopes, 98-15 and 
98-18, exhibited significant infection on macrophages. 
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FIG. 3-2. gp160 alignment of pediatric AIDS patient P1114. The gp160 sequences of 
envelopes isolated from P1114, including 98-15, 98-18, 98-27, 98-28, and 98-67.  
There are slight differences between these envs, but the only polymorphisms 
corresponding to phenotypic changes are found in the V1/V2 region of gp160.  The 
numbering used in this alignment is not relative to HXB2 numbering.  The non-
macrophage-tropic envelopes all have E114 and D129 (E153 and D167 relative to 
HXB2 numbering). These residues are the only candidates that could explain the 
differences in macrophage infectivity between these envelopes.  
42
 
Env 98-18 confers more modest levels of macrophage infectivity and possesses 
only the D167N change. The non-macrophage-tropic envelopes all have E153 
and D167. These residues are the only candidates that could explain the 
differences in macrophage infectivity between these envelopes. 
3-4 Macrophage infectivity of envelopes mutated at residues 153 and 167: 
To determine whether the two polymorphisms in the V1/V2 region of these 
envelopes were responsible for the differences in macrophage infectivity, point 
mutations were made by site-directed mutagenesis and infectivity evaluated on 
TZM-BL cells and macrophages. A G153E substitution in 98-15 abolished 
macrophage tropism, which is consistent with the requirement of G153 for 
macrophage infectivity. In contrast, an N167D substitution in 98-15 had no effect 
on macrophage infectivity, while a combination of G153E and N167D 
substitutions conferred the same loss of macrophage infectivity as the G153E 
substitution alone (Fig. 3-4).  
The reciprocal substitutions were then made in the non-macrophage tropic 
envelopes, 98-27 and 98-28. For both of these envelopes, E153G caused a 
drastic increase in macrophage infectivity, approximately equal to the level of the 
98-15 wild-type (wt) envelope. In contrast, D167N did not confer any significant 
increase in macrophage infectivity for 98-27 and 98-28. For 98-18, E153G 
enhanced the modest levels of macrophage infection conferred by this envelope 
to levels similar to 98-15, whereas N167D abrogated macrophage infection. 
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 Taken together, these results indicate that G153 is the major determinant  
 
 
FIG. 3-3. Specific envelope residues in the V1V2 loops segregate with 
macrophage infectivity. Aligned V1V2 sequences from C3 disease stage 
envelopes show that E153 and D167 in boxes are found in non-macrophage-
tropic envelopes. 98-15 is the only envelope carrying G153 and is the most 
macrophage tropic. Both 98-15 and 98-18 have N167, but 98-18, which has 
intermediate macrophage infectivity, lacks G153.  
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responsible for the macrophage-tropic phenotype observed for the C98-15 
envelope, while N167 conferred only modest effects on macrophage infectivity 
for 98-18. 
3-5 Residue E153 is conserved across HIV-1 clades: 
The frequencies of E and G at position 153 were then evaluated for other 
HIV-1 clade B and non-B clades. In clades A, B, and C, residue E153 is highly 
prevalent, a situation similar to the non-macrophage-tropic envs evaluated in the 
present study, whereas G153 is less common (Table 3-1).  Interestingly, G153 is 
more prevalent in clades D and CRF02-AG, while for clade G and CRF01-AE, 
E153 was less prevalent but was not frequently substituted with a G.  The 
conservation of E153 is also apparent in the review by Zolla-Pazner and Cardozo 
[146].  
3-6 The E153G substitution confers macrophage infectivity for heterologous 
clade B envelopes: 
Since E153 is relatively conserved, it was next investigated whether the 
E153G substitution conferred macrophage infectivity for heterologous envs or 
was limited to the pediatric envelopes described here.  I introduced the E153G 
substitution into four heterologous clade B R5 envelopes that carry E153 in the 
V1 loop (NA20 LN8, NA118 LN27, NA420 LN40, and JRCSF) and that are non-
macrophage-tropic.  For two of the envelopes, LN27 and JRCSF [89, 91], the 
E153G substitution conferred substantial levels of infectivity for macrophages 
(Fig. 3-5).  The effects of the reverse G153E substitution into a highly 
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a Residue E153 is conserved across clades. V1 sequences were obtained from 
the HIV database (http://www.hiv.lanl.gov/content/index) for clades A, B, C, D, 
G, AE, and 02AG. These sequences were aligned using CLUSTAL W2 and 
manually corrected. E153 is highly conserved across clades A, B, and C. G153 is 
most prevalent in clades D and 02AG. 
  
TABLE 3-1. Conservation of V1 loop residue 153 
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FIG. 3-4. V1 loop residue 153 modulates macrophage tropism. A G153E 
substitution in macrophage-tropic R5 C98-15 reduced macrophage infectivity by 
at least a 100-fold, while N167D had only a modest effect (top, left panel).  For 
98-18 (top, right panel), E153G enhanced modest macrophage infectivity to 
levels similar to 98-15 wt, whereas N167D abrogated macrophage infection to 
levels close to background.  For non-macrophage-tropic envelopes (98-27 and 
98-28; bottom panels), an E153G substitution conferred 100-fold increase in 
macrophage infectivity.  In contrast, a D167N substitution had only modest 
effects on these two envelopes. Double substitutions at residues 153 and 167 
conferred phenotypes similar to the single change at residue 153, although this 
was less evident for 98-28. These data show that residue 153 alone modulates 
macrophage infectivity.  
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macrophage-tropic brain-derived envelope, FL5-2-209, that naturally carried a G 
at residue 153, was then investigated.  However, this change had no effect on 
the capacity of FL5-2-209 to infect macrophages (Fig. 3-5).  Finally, E153G 
substitutions into clade C (25925-2) and D (CMT19 S531) envelopes were made.  
However, these envelopes remained non-macrophage-tropic. In summary, 
substitution of V1 loop residue E153 with G conferred macrophage tropism for 
two of four heterologous clade B envelopes tested. 
3-7 Substitutions in V1 loop residue 153 affect sensitivity to neutralizing 
antibodies and entry inhibitors: 
(i) MAb b12 and sCD4  
The capacity of HIV-1 R5 envelopes to infect macrophages correlated with 
infection of indicator cell lines via low levels of CD4 [91, 96, 98, 139].  The ability 
to use low levels of CD4 for infection was shown previously to be due to changes 
within or proximal to the CD4bs [104, 105], which presumably confer an 
increased envelope avidity for cell surface CD4.  Such changes in the use of 
CD4 are usually evident in shifts in the sensitivity of envelopes to inhibition by 
soluble CD4 and the CD4bs MAb, b12, with sensitivity to b12 a reasonable 
surrogate for the exposure of the CD4bs on many clade B envelopes.  However, 
residue 153 is in the V1 loop, which has been proposed to sit at the apex of the 
envelope trimer away from the CD4bs [56].  It was tested whether substitutions at 
residue 153 affected sensitivity to sCD4 and b12.  For the non-macrophage-
tropic envelopes where E153G substitutions increased macrophage tropism (98- 
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FIG. 3-5. V1 loop residue 153 modulates macrophage tropism for two of seven 
heterologous R5 envelopes. The E153G substitution was introduced into four 
heterologous, non-macrophage-tropic clade B R5 envelopes. For two (LN27 and 
JRCSF; top panels), the substitution conferred at least a 100-fold increase in 
macrophage infectivity. In contrast, E153G had no effect on the lack of macrophage 
infection conferred by LN8 and LN40 (second panels down). The reverse substitution 
G153E in the highly macrophage-tropic FL5-2-209 also had no effect on the high levels 
of macrophage tropism conferred by this envelope (third panel down, left). Finally, 
E153G substitutions in clade C (25925-2) (third panel down, right) and clade D (CMT19 
S531) (bottom panel) envelopes also failed to affect their lack of macrophage infection. 
E153G substitutions thus conferred macrophage tropism for two of seven heterologous 
HIV-1 R5 envelopes. 
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27, 98-28, LN27, and JRCSF), there were dramatic increases in sensitivity to 
sCD4 reflected in decreased 50% inhibitory concentrations (IC50s) of 50- to 100-
fold (Fig. 3-6 A, left panels). We also noted more modest shifts in b12 sensitivity 
for these envelopes. Thus, for envelopes with E153G, IC50 shifts of around 10-
fold were observed for b12 inhibition. For the macrophage-tropic envelope 98-15, 
the reverse G153E substitution (which abrogated macrophage infection) 
conferred decreased sensitivity to sCD4 with an increased IC50 of about 50-fold 
observed but only a minimal shift in b12 sensitivity at best.  Nevertheless, these 
changes in sCD4 and b12 sensitivity are consistent with effects on the CD4bs 
mediated by residue 153 in the V1 loop.  
The effects of the E153G substitution on sCD4 and b12 sensitivity for 
envelopes that failed to switch tropism were then investigated.  For LN8 and 
LN40, E153G had no significant effect on sCD4 or b12 sensitivity (Fig. 3-6 B). 
However, for both the clade C (25925-2) and clade D (CMT19 S531) envelopes, 
E153G increased their sensitivity to sCD4, although there was no change for 
b12.  The clade D envelope (CMT19 S531) stayed resistant to b12, and this may 
reflect the reduced crossreactivity of b12 for this clade [147].  Interestingly, the 
reverse G153E substitution in the highly macrophage-tropic FL5-2-209 envelope, 
which naturally carries G153, conferred substantial decreases in sensitivity to 
sCD4 and b12, even though the mutant envelope still conferred high levels of 
macrophage infection.  
Together, these results show that the V1 loop residue at 153 frequently 
50
FIG. 3-6. Substitutions at residue 153 in the V1 loop modulate sensitivity to sCD4 
and b12 in addition to macrophage tropism. (A) The five R5 envelopes that 
switched macrophage tropism following E153G (C98-27, C98-28, LN27, and 
JRCSF) or G153E (C98-15) substitutions showed changes in sensitivity to sCD4 
and to b12. (B) The five R5 envelopes that failed to switch macrophage tropism 
following E153G (LN8, LN40, 25925, and CMT19S531) or G153E (FL5-2-209) 
substitutions were also tested for changes in sensitivity to sCD4 and b12. 
Despite no change in tropism, changes in sensitivity to these reagents were 
detected for some but not all of the envelopes. Nonetheless, consistent changes 
in sCD4 and b12 sensitivity were associated with changes in macrophage 
tropism. 
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confers alterations in the CD4bs affecting sensitivity to sCD4 and b12.  Of note, 
changes in sCD4 sensitivity sometimes occurred in the absence of detectable 
changes in macrophage tropism.  Nevertheless, envelopes that did switch 
tropism generally showed the largest changes in sensitivity to sCD4 and b12. 
(ii) The V3 loop-specific MAb, 447-52D:  
Dramatic changes in sensitivity to the V3 loop MAb, 447-52D, were also 
observed for envelopes that switched macrophage tropism after substitution at 
residue 153.  For the non-macrophage-tropic envelopes where E153G conferred 
macrophage infection, there were large increases in sensitivity to 447-52D with at 
least 100-fold decreases in IC50s (Fig. 3-7).  In contrast, for 98-15, G153 
conferred resistance to 447-52D to go alongside the abrogation of macrophage 
infection (Fig. 3-7).  
For LN8 and LN40, the E153G mutant envelopes remained resistant to 
447-52D consistent with the lack of an effect on their non-macrophage tropism. 
For the macrophage-tropic brain Env FL5-2-209, G153E conferred resistance to 
447-52D even though it had no effect on macrophage infectivity.  Overall, these 
observations indicate an intriguing role for the V3 loop in R5 macrophage tropism 
that could be associated with effects on the CD4bs or in altered interactions with 
CD4 or CCR5.  These possibilities are addressed below. 
(iii) Other entry inhibitors and neutralizing antibodies: 
The same envelopes and mutants were also tested for sensitivity to 
neutralizing MAbs and inhibitors that target different envelope sites or functions. 
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FIG. 3-7. Sensitivity to the V3 loop-specific MAb, 447-52D, is modulated by 
substitutions at residue 153 and associated with switches in macrophage 
tropism. For R5 envelopes with altered macrophage tropism following E153G 
(C98-27, LN27, and JRCSF) or G153E (C98-15) substitutions, there were 
substantial changes in sensitivity to the V3 loop mAb 447-52D (left panels). For 
three envelopes that failed to switch tropism following E153G substitution, there 
were no changes in 447-52D sensitivity. However, FL5-2-209 showed decreased 
sensitivity to 447-52D following the reverse substitution, even though this change 
failed to affect high levels of macrophage infectivity (right panels). In summary, 
substantial changes in sensitivity to the V3 loop MAb, 447-52D, were associated 
with changes in macrophage tropism following substitutions at V1 loop residue 
153. 
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Table 2 shows IC50s for envelopes tested.  Overall, E153G and G153E had no 
substantial effect on sensitivity to the glycan-specific MAbs 2G12, 17b, 
maraviroc, 2F5, or T20.  These observations indicate that the substitutions at 
residue 153 affect the CD4bs but do not confer a more global effect on other 
envelope functions, including interactions with CCR5 (maraviroc) or gp41 
conformational changes required for fusion (2F5 and T20), nor do they result in 
increased exposure of the CD4i epitope (17b).  Of note, the lack of change in 
maraviroc sensitivity suggests that alterations in the V3 loop that confer shifts on 
447-52D sensitivity do not impact on the efficiency of Env-CCR5 interactions, 
although this needs to be verified through further experimentation. 
3-8 Residue 153 is proximal to conserved V1/V2 determinants that are targeted 
by broadly active neutralizing MAbs: PG9 and PG16:  
Two human MAbs, PG9 and PG16, that were derived from a clade A-
infected African donor were reported [148].  These MAbs are able to neutralize 
pseudovirions expressing a wide range of diverse envelopes [148].  They 
preferentially bind to the trimeric envelope and target an epitope that involves 
determinants in the V2 and V3 loops [148].  The proximity of the V2 determinants 
to V1 residue 153 in the V1 loop and the implication of the V3 loop in 
macrophage tropism prompted us to test whether envelopes carrying E153G or 
G153E substitutions differed in sensitivity to PG9 or PG16.  Some shifts in 
sensitivity to PG9 and PG16 were noted (Table 3-2).  However, these were 
mainly modest and did not segregate with macrophage infectivity. 
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TABLE 3-2. Sensitivity of R5 envelopes and their corresponding mutants with V1 loop 
residue 153 substitutions to various entry inhibitors and neutralizing antibodies 
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3-9 DISCUSSION: 
Here it is shown that a single amino acid substitution in the V1 loop 
modulates macrophage tropism for heterologous HIV-1 clade B R5 envelopes. 
The structures of the V1 and V2 loops have recently been solved bound to the 
MAb PG9 [48], although their structure in the context of gp120 is still not 
resolved.  Various studies showed that the V1 and V2 loops influenced the 
binding of CD4bs MAbs, suggesting that these loops may help to shield the 
CD4bs [149-152].  Electron tomographic structures, including a recent high 
resolution structure of the trimeric envelope, strongly suggest that the bulk of the 
V1 and V2 loops sit on the apex of the trimeric envelope and thus some distance 
from the CD4bs [56].  This data is consistent with a model where the V1 loop 
determinant affects the ability of the V1/V2 and V3 loops to separate and expose 
the V3 loop in response to CD4 binding.  The increased efficiency of V1/V2 
conformational shifts increases the ability of the envelope to exploit low CD4 use 
for macrophage infection.  Moreover, it is striking that V1 residue 153 control of 
the V3 loop and CD4bs was active for envelopes derived from three of six clade 
B-infected subjects.  This mechanism is thus likely to be operative for up to 50% 
of clade B envelopes.  
Previously several determinants have been reported to have major effects 
on macrophage infection by HIV-1 R5 envelopes.  These include residue 283 in 
the CD4bs [98, 104, 105] and residues adjacent to the CD4 contact residues on 
the CD4 binding loop [105].  Thus, macrophage tropism can be modulated by 
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changes within the CD4bs, which directly impact Env-CD4 affinity, or by changes 
that indirectly affect the CD4bs, presumably by affecting the exposure CD4 
contact residues.  The identification of a distal V1 loop determinant that also 
confers macrophage tropism is striking and indicates that multiple envelope sites 
may have the potential to modulate macrophage tropism.  
The change from a charged glutamic acid (E) to the uncharged glycine 
could have profound effect on the interaction of the V1 loop with other envelope 
residues due to the loss of potential ionic bonds.  The initial interpretation was 
that the V1 determinant acted by affecting the exposure of CD4 contact residues. 
However, shifts in b12 sensitivity (an indicator of CD4bs exposure) following 
substitutions at residue 153 ranged from extremely minor to modest at best and 
were substantially smaller than for sCD4 or 447-52D.  It is therefore unlikely that 
the effects of V1 residue 153 result entirely from increased exposure of CD4bs 
residues.  Thus, changes in the capacity of the envelope to react to suboptimal 
levels of cell surface CD4 (without changes in Env-CD4 affinity) and trigger 
conformational changes and viral entry should be considered as an alternative 
mechanism (see below).  
For envelopes where the substitution in V1 did not affect tropism, changes 
in sCD4, b12, and 447-52D sensitivity were noted for some but not other 
envelopes.  For envelopes that showed no change in sCD4, 447-52D, and b12 
sensitivity, it is possible that a putative connection between the V1 and V3 loops 
is absent or held by alternative mechanisms, so that residue 153 substitutions 
57
have no effect on the CD4bs.  Alternatively, other determinants that affect the 
CD4bs and macrophage tropism may simply override any effects conferred by 
changes in the V1 loop determinant.  This latter possibility could apply to the 
highly macrophage-tropic brain envelope FL5-2-209.  This envelope was initially 
highly sensitive to sCD4, 447-52D, and b12 (IC50s of 0.34, 2.0, and 2.5 µg/ml, 
respectively) but became substantially more resistant (IC50s of 7.5, 50, and 11.8 
µg/ml, respectively) when the G153E substitution was introduced, even though 
no changes in macrophage infection were observed.  It is thus likely that 
alternative envelope residues confer macrophage infectivity and simply override 
the effects of V1 residue 153.  It is noteworthy that an E153G substitution was 
previously reported to be responsible for increased syncytium formation following 
infection of brain microglial cultures by an HIV-1 R5 variant selected in vitro 
[153].  
The C98-18 envelope conferred modest levels of macrophage infection 
compared to the highly macrophage-tropic C98-15 and the non-macrophage-
tropic P1114 envelopes.  C98-18 carries the D167N substitution in the V2 loop 
but not the V1 loop E153G substitution present in the C98-15 envelope.  An 
N167D substitution in C98-18 abrogated the modest levels of macrophage 
infection confirming the role of this residue (Fig. 3-4).  In addition, N167D 
conferred an increase in the sensitivity of C98-18 to sCD4, reducing the IC50 
from 26.62 to 8.19 µg/ml, but had no affect on the resistance to the V3 loop MAb, 
447-52D (data not shown).  These observations are curious since substitutions at 
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residue 167 had no effect on the macrophage infectivity of the other P1114 
envelopes tested.  Presumably, there are other determinants in the P1114 
envelopes that influence whether residue 167 affects macrophage infectivity.  
Regardless, the data indicate that V2 residue 167 is only a minor player in the 
macrophage tropism of the P1114 envelopes.  
Other studies have also reported single or limited substitutions in the 
envelope that affect macrophage infectivity and/or sensitivity to neutralizing 
antibodies.  Lynch et al. reported that the introduction of a leucine residue to 
replace a highly conserved isoleucine (I309) in the V3 loop of clade C envelopes 
affected the exposure of the CD4bs and conferred an increase in macrophage 
replication, although this was modest [154].  Li et al. described an N197Q 
substitution proximal to V2, which removed a potential N-linked glycosylation site. 
N197Q conferred increases in sensitivity to sCD4 and b12.  However, N197Q 
also conferred sensitivity to 17b, a CD4i MAb, indicating that more substantial 
structural changes had resulted that exposed sites involved in coreceptor binding 
[155].  Similarly, Zhu et al. reported on an adjacent substitution in the β3 strand, 
T198P [156], while O’Rourke et al. described a D179N substitution in the LDV 
motif of V2 [150], both of which conferred global neutralization sensitivity and 
exposure of the 17b epitope.  Some of these substitutions may affect the 
interactions of the gp120 subunits on the trimer, perhaps altering the position of 
the V1V2 loops, which may interact at the apex.  Such changes may also result 
in triggering some of the conformational changes (usually associated with CD4 
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binding) and exposure of CD4i epitopes.  
Limited changes in the extracellular segment of gp41 have also been 
shown to affect neutralization sensitivity.  Thus, two amino acid changes in the 
conserved HR1 and MPER regions in gp41 together conferred increased 
sensitivity to sCD4, broadly neutralizing gp120 and gp41 MAbs, and to human 
HIV-1+ plasmas [157].  In addition, Shen et al. recently reported an L669S 
substitution in the MPER that conferred increased sensitivity to a range of gp41- 
and gp120-specific neutralizing MAbs.  Presumably, these substitutions also act 
indirectly by influencing the arrangement of gp120 subunits on the trimer and 
thus affecting their sensitivity to neutralizing antibodies.  
In contrast, the effects of V1 residue 153 are unique in conferring large 
shifts in envelope phenotype that are focused specifically on the V3 loop and 
CD4bs without major effects on other envelope sites, as estimated by envelope 
sensitivity to inhibitors that targeted other stages of HIV-1 entry, including Env-
CCR5 interactions and gp41 conformational changes.  All envelopes also 
remained relatively resistant to 17b, a CD4i MAb, indicating that extensive 
conformational changes that are usually associated with gp120-CD4 interactions 
had not occurred.  The changes affected by V1 residue 153 thus contrast with 
the substitutions described above [155].  
These experiments indicate that V1 residue 153 has strong affects on the 
V3 loop and the CD4bs, which are only partially explained by increased exposure 
of the CD4 contact residues.  On the unliganded envelope, the V3 loop may sit 
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close enough to restrict the approach of both CD4 and b12 [56, 158].  It is also 
tempting to envisage that residue 153 modulates a gp120 conformational change 
to form a structure intermediate between the unliganded envelope and the CD4-
bound form.  Such an intermediate may be partially activated for the 
conformational changes required to form the coreceptor binding site and thus 
require less robust interactions with fewer CD4 molecules to trigger fusion and 
infection.  
The determinant at residue 153 is proximal to sites in the V2 loop that are 
targeted by the recently described MAbs PG9 and PG16 [148].  In fact, these 
MAbs target determinants in both the V2 and the V3 loops.  Since the 
substitutions in V1 described here also had effects on the V3 loop, we 
hypothesized that they would impact on PG9 and PG16 sensitivity.  However, 
only modest effects on PG9 and PG16 sensitivity were observed.  This result 
illustrates the robustness of the PG9 and PG16 epitope and is a reassuring result 
for vaccine research focused on this epitope.  
The conservation of glutamic acid at position 153 across several clades is 
intriguing and implies that this site plays an important functional role for the 
envelope.  Our data suggest that this role may involve an interaction with the V3 
loop, which in turn affects the CD4bs.  The decreased frequency of E153 among 
clade D and CRF02_AG envelopes and increased frequency of G153 is also 
striking.  Whether the higher prevalence of G153 associates with increased 
macrophage tropism for these clades is not known.  An E153G substitution for 
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the one clade D envelope that we tested (CMT19 S531) had no affect on 
macrophage tropism.  However, a more extensive survey would be needed to 
establish an influence of G153 on clade D or CRF02_AG envelopes.  Of note, 
clade D viruses have been associated with faster disease progression [159-163] 
and a higher frequency of dementia [164].  In addition, CXCR4 tropism was 
common among CRF02_AG viruses, a sign of a mature HIV epidemic [165].  It is 
thus possible that an increased frequency of G153 may simply reflect a high 
prevalence of R5 viruses with increased macrophage tropism late in disease [99-
101].  
In summary, we describe here a novel determinant in the V1 loop that 
modulates macrophage tropism conferred by HIV-1 R5 envelopes.  The V1 loop 
determinant appears to control the exposure or conformation of the V3 loop, 
which in turn impacts the CD4bs to prime the envelope for low CD4 use and 
macrophage infection.  Our data also have relevance for vaccines that aim to 
target the CD4bs.    
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CHAPTER IV: HIV-1 R5 NON-MAC TROPIC ENVELOPE 
GLYCOPROTEINS DO NOT CONFER AN ENHANCED TROPISM 
FOR CD4+ T-CELLS COMPARED TO HIGHLY MAC-TROPIC 
VARIANTS 
4-1 Introduction: 
As described previously, HIV-1 viruses using CCR5 (R5) vary extensively 
in their ability to infect macrophages.  Thus, macrophage-tropic R5 strains can 
exploit the low levels of cell surface CD4 on macrophages for infection, while 
non-macrophage-tropic R5 viruses that require high levels of CD4 for infection 
cannot [91, 98, 104].  Determinants that modulate R5 macrophage infection have 
been mapped to residues within or proximal to the CD4 binding site of gp120 
[104, 105, 139], although as described previously here, a single substitution of a 
conserved V1 loop residue modulated macrophage infection for some but not all 
R5 envelopes [166]. Amongst R5 viruses, non-macrophage tropic strains 
comprise the majority of transmitted or founder viruses [117, 119, 167] and are 
predominant in immune tissue [91, 98] even at late stages of disease when 
macrophage-tropic variants can be increasingly detected in blood [99-101] or 
brain tissue [108].  Nonetheless, the contribution of non-macrophage-tropic and 
macrophage-tropic R5 viruses to HIV-1 pathogenesis of HIV-1 remains relatively 
uncharacterized.   
The predominance of non-macrophage-tropic R5 viruses in immune tissue 
strongly indicates that they have a selective advantage over more macrophage-
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tropic variants. However, it is unclear how this advantage is manifested. Previous 
data by Peters PJ et al. showed that infection of primary CD4+ T-cells conferred 
by macrophage-tropic R5 envelopes was at least as efficient as for non-
macrophage-tropic counterparts [168], while both mac-tropic and non-mac-tropic 
Env+ pseudovirions show similar sensitivities to heterologous HIV-1+ human 
sera (P. Clapham, unpublished observations) [157].  
Like macrophages, mDCs express only low levels of CD4 [127].   
Nonetheless, immature mDCs were reported to be more susceptible to infection 
compared to mature DCs [123, 169], even though they express SAMHD1, a post-
entry HIV-1 restriction also expressed in monocytes [73, 74]. Myeloid DCs also 
efficiently capture HIV via interactions with DC-SIGN or other mechanisms [170, 
171] and then present and transfer infectious virus particles to CD4+ T-cells 
during DC: T-cell interactions [172-174].  Nevertheless, the role of myeloid 
dendritic cell (mDC) infection and trans-infection in HIV-1 disease progression is 
unclear. 
Here, I investigated whether mDCs are sensitive to infection mediated by 
pseudovirions carrying macrophage-tropic and non-macrophage-tropic R5 
envelopes (including early founder and acute stage envelopes [116]) and 
whether they influence infection of CD4+ T-cell infection via their capacity to 
present virions via cis and trans mechanisms.  It is demonstrated here that only 
mac-tropic envelopes could confer infection of MDDCs.  In contrast, efficient 
infection of CD4+ T-cells was observed for both mac-tropic and non-mac-tropic 
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R5 Envs, although infection by mac-tropic Envs was consistently highest.  
Nevertheless, equivalent infection of CD4+ T-cells by non-mac-tropic and mac-
tropic R5 envelopes was observed if virions were first captured and presented by 
mDCs.  The data presented here reveal that trans-infection (via capture and 
presentation of virions by DCs) is critical in conferring maximal infection of CD4+ 
T-cells by non-macrophage-tropic R5 viruses and is likely to be an important 
mechanism for such strains to become predominant in immune tissue.  
Results 
4-2 Envelope+ pseudovirions for infectivity assays: 
A panel of well-characterized Envs was selected for investigation (Table 4-
1). The panel included Env pairs from separate individual subjects, where each 
pair comprised one that is highly mac-tropic and one that is non-mac-tropic. 
Several of these individuals were AIDS subjects with dementia or other 
neurological complications [108].  One set of Envs was derived from a chronic 
stage pediatric patient described in the previous chapter.  P43 Envs were derived 
from the blood and semen of an acutely infected individual.  Most of these Envs 
have been previously characterized with respect to their macrophage tropism 
and were selected for this study based upon these previous results [97]. Env+ 
pseudovirions carrying a GFP reporter gene were prepared for infectivity assays 
described throughout this study. We first tested for infection of HeLa TZM-bl cells 
and macrophages. GFP+ cells were counted 2 days post- 
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Table 4-1 Patients and Envelopes used in pseudotype studies. 
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infection for HeLa TZM-bl cells and 5-7 days post infection for macrophages.   
Both non-mac-tropic and mac-tropic Envs conferred strong infection of 
HeLa TZM-bl cells that express high levels of CD4 and CCR5.  Nonetheless, 
mac-tropic Envs consistently conferred between 5- and 20-fold higher infectivity 
titers compared to non-mac-tropic Envs (Fig. 4-1 A). All of those envelopes 
previously determined to be mac-tropic conferred high levels of infectivity for 
macrophages as expected with infectivity titers that were several orders of 
magnitude higher than for non-mac-tropic Envs (Fig. 4-1 B). Since the non-
macrophage-tropic R5 Envs conferred lower levels of infectivity on HeLa TZM-bl 
cells that carry high levels of CD4 and CCR5 [134], we measured the levels of 
gp120 present in each pseudovirion preparations to establish whether 
differences in envelope expression levels might be an explanation. However, no 
significant difference between the amount of gp120 present in non-mac-tropic 
and mac-tropic Env+ pseudovirion preparations was detected (Fig. 4-1 C).  
4-3 Infection of MDDCs by pseudovirions expressing mac-tropic and non-mac-
tropic R5 Envs: 
 We next investigated whether myeloid dendritic cells (mDCs) were 
susceptible to infection by mac-tropic or non-mac-tropic Env+ pseudovirions. 
mDCs are derived from the same cell lineage as monocytes and macrophages 
and like macrophages, express low levels of CD4 [127].  However, CCR5 
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FIG. 4-1. Envelopes selected from the same patient differ significantly in their 
ability to infect macrophages. R5 envelopes were amplified from the patients 
detailed in table 3 and used to generate GFP reporter env+ pseudovirions.  (A) 
The macrophage tropic isolates had slightly higher infectivity on HeLa TZM-bl 
cells than the non-macrophage tropic isolates.  All were able to significantly infect 
the TZM-bls.  (B) Mac-tropic isolates infect monocyte-derived macrophages 
around 1000-fold better than the non-mac-tropic isolates.  These are mean 
values from three separate donors.  (C) There is no significant difference 
between the amount of gp120 detected in the viral supernatants between mac 
and non-mac tropic env+ pseudovirions.   
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expression on mDCs was also reported to be low [141, 175].  Myeloid DCs 
express SAMDH1, an HIV restriction factor that is also expressed in monocytes 
[73, 74].  The low levels of CD4 and CCR5, as well as SAMHD1 expression has 
led to a consensus view that these cells are relatively insensitive to HIV-1 
infection in vivo.  In this study, we prepared mDCs from blood monocytes using 
standard (IL-4, GM-CSF) differentiation protocols [127].  These monocyte-
derived dendritic cells express DC-SIGN [128].  Flow cytometry analysis showed 
that MDDCs expressed CD11c, an integrin marker for DCs, but were around 
90% negative for the monocyte marker CD14 (Fig. 4-2 A).  The dendritic cell 
specific maturation marker CD83 shows that the LPS-matured DCs are distinct 
from the immature MDDCs.  There is a small amount of CD4 expression on 
these MDDCs, consistent with what has been previously reported (Fig. 4-2 B).  
The levels of CCR5 are very low, while there is a slightly higher level of CXCR4 
expression on these cells.  In addition, the morphology of MDDCs by light 
microscopy was typical for DCs, and they immunostain positive for CD11c (Fig. 
4-2 C). 
 We tested infection of MDDCs with our panel of GFP-reporter Env+ 
pseudovirions. MDDCs were susceptible to mac-tropic Envs (with the exception 
of 98-15) (Fig. 4-3), but were approximately 10-20 times less sensitive compared 
to macrophages. Moreover, all of the non-mac tropic Envs including the 
founder/acute stage envelopes conferred background or very weak infection of  
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FIG. 4-2. Characterization of MDDCs.  Monocytes were differentiated for 7 days 
in GMCSF + IL-4.  MDDCs were stained and analyzed by flow cytometry.  (A) 
The majority of the cells express CD11c, while 11.7% still express CD14.  
Autologous LPS-matured DCs were stained for CD11c and CD83. (B) MDDCs 
express low amounts of CD4, and low amounts of CCR5.  They do express 
slightly higher amounts of CXCR4 than CCR5.  (C) From left to right, phase 
contrast, MDDCs infected with JRFL GFP-reporter Env+ pseudovirions, and the 
same MDDCs immunostained with CD11c.   
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FIG. 4-3. Infection of MDDCs by pseudovirions expressing mac-tropic and non-
mac-tropic R5 envelopes.  Monocytes were differentiated for 7 days in GMCSF + 
IL-4.  Env+ pseudovirions were used to infect MDDCs and infection was 
quantified 5-7 days post infection. On the left are the titers of the Envs used.  On 
the right is a comparison between mac-tropic and non-mac tropic Envs on 
MDDCs.  Only Mac-tropic Envs are capable of infecting MDDCs. These are 
mean values from three separate donors.  P values were generated using the 
Mann-Whitney T-test.   
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the MDDCs, with only JRCSF and 7766 SP envelopes conferring detectable 
infection (not shown in Fig. 4-3).  
4-4 LPS matured MDDCs support infection by mac-tropic but not non-mac-tropic 
Env+ pseudovirions: 
Previous studies showed that immature DCs are more sensitive to 
infection than mature or activated DCs [123].  To determine if the maturation 
state of MDDCs plays a role in infection by mac-tropic and non-mac tropic Envs, 
we prepared MDDCs treated with 100 ng/ml of LPS.  These matured MDDCs 
expressed significant levels of CD83 (46.9% positive for CD83, MFI 64.4), a 
marker of myeloid DC maturation, and formed a distinctive morphology by light 
microscopy (Fig. 4-2 A).  However, the MDDCs not treated with LPS used in Fig. 
4-2 also expressed significant levels of CD83 (51.2% positive for CD83, MFI 
76.1).  These non-LPS treated MDDCs may have been inadvertantly subjected to 
stimuli caused maturation.  Other donors have shown 9.9% of non-LPS treated 
MDDCs positive for CD83 (MFI of 26.7).  Further flow cytometry analysis will 
need to be done to definitively demonstrate a maturation difference upon LPS 
treatment, although a morphological difference was apparent in all donors.  I then 
infected these LPS treated MDDCs alongside autologous non-LPS treated 
MDDCs shown in Fig. 4-4.  Mac-tropic R5 Envs conferred similar levels of 
infection on LPS treated and untreated DCs.  Infection of both populations of 
MDDCs by pseudovirions carrying non-mac-tropic Envs was either at 
background levels or extremely weak.   
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FIG. 4-4. Mac tropic Envs infect both mature and immature MDDCs.  Monocytes 
were differentiated for 7 days in GMCSF + IL-4, and either allowed to remain 
naïve or treated with LPS.  Env+ pseudovirions were used to infect MDDCs and 
infection was quantified 5-7 days post infection. On the left are the mac-tropic 
Envs, and on the right are the non-mac tropic Envs.  Only Mac-tropic Envs are 
capable of infecting MDDCs, and they infect both mature and immature MDDCs 
similarly.  These are mean values from two separate donors. 
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4-5 Infection of PBMCs and CD4+ T-cells by mac-tropic and non-mac-tropic R5 
Env+ pseudovirions: 
Non-mac-tropic R5 variants are predominant in immune tissue, where 
CD4+ T-cells expressing high levels of CD4 are presumably targeted [98].  I next 
investigated whether non-mac-tropic R5 Envs have an increased ability to confer 
infection of PBMCs or CD4+ T-cells infection compared to mac-tropic Envs.  
PBMCs and autologous purified CD4+ T-cells obtained from three separate 
donors were stimulated with PHA and IL-2 and tested for their sensitivity to 
infection 2 days later.  Both mac-tropic and non-mac-tropic R5 Envs conferred 
efficient infection of both PBMCs and CD4+ T-cells.  However, mac-tropic R5 
Envs displayed a trend to higher infectivity titers for both cell cultures compared 
to non-mac-tropic R5 Envs (Fig. 4-5).  Although results for individual donors were 
not significant, they become highly significant if all the data are combined across 
donors (p<0.0001).  This result confirms previous observations made with just 
three mac-tropic and 3 non-mac-tropic R5 envelopes in the context of replication 
competent viruses [98]. 
4-6 MDDCs enable efficient T-cell infection by non-mac-tropic envelopes: 
DCs capture HIV-1 particles and present them to CD4+ T-cells, thereby 
increasing the efficiency of infection via virological synapses [172, 176, 177].  It 
was first evaluated whether non-macrophage-tropic or macrophage-tropic Envs 
were preferentially transmitted by MDDCs, and whether MDDCs that were first 
treated with Env+ pseudovirions could confer efficient infection of autologous  
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FIG. 4-5. Macrophage tropic envelopes trend to better directly infect PBMCs and 
CD4+ T-cells. 100µL of GFP-reporter viral supernatant was titrated on PBMCs or 
enriched CD4+ T-cells, and infectivity was quantified 2dpi.  (A) Three separate 
donors were used to generate PBMC cultures.  Macrophage tropic Envs infected 
PBMCs slightly better than their non-macrophage tropic counterparts.  (B) The 
same trend of mac-tropic Envs better infecting PBMCs is seen using CD4+ T-
cells with three separate donors.  P values were generated using the Mann-
Whitney T-test.   
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FIG. 4-6. Trans-infection of CD4+ T-cells is as efficient for non-macrophage 
tropic envs as for macrophage tropic envs. 100µL of GFP-reporter viral 
supernatant was incubated with MDDCs for 1 hr.  The MDDCs were then washed 
twice and co-cultured with autologous target cells, which were assayed for 
infectivity 2 days post co-culture.  (A) Three separate donors were used to 
generate PBMC cultures.  Non-macrophage tropic Envs infected PBMCs as well 
as macrophage tropic Envs.  (B) CD4+ T-cells from three separate donors were 
as readily infected by non-macrophage tropic Envs as by mac-tropic Envs.  (C) 
Trans-infection of PBMCs was done using LPS-matured MDDCs.  (D) To 
determine the amount of virus captured, MDDCs were incubated with viral 
supernatant for 1 hr, then washed twice and used in a p24 ELISA.  No significant 
differences were observed.  P values were generated using the Mann-Whitney T-
test.   
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PBMCs or CD4+ T-cells.  MDDCs were treated with virus for one hour 
before washing and co-culturing with autologous PHA, IL-2 stimulated PBMCs or 
CD4+ T-cells.  In this infectivity system both mac-tropic and non-mac-tropic Envs 
conferred efficient and similar (not significantly different) infection of both PBMCs 
and CD4+ T-cells (Fig. 4-6 A-B).  To determine if the maturation state of the 
MDDCs played a significant role in this trans infection, MDDCs were first 
activated with LPS, and used in the same experiment.  These matured  
MDDCs yielded similar levels of trans-infection as those not treated with LPS 
(Fig. 4-6 C).   
In order to address whether or not mac-tropism effects virion capture by 
the MDDCs, and thereby has an effect on the subsequent transmission of the 
captured virions, the amount of virus that had bound was then estimated by 
measuring the amount of cell associated p24 antigen by ELISA.  MDDCs were 
incubated with virus and washed as before.  There was no significant difference 
in the amount of p24 bound to MDDCs between macrophage-tropic and non-
macrophage-tropic Env+ pseudovirions (Fig. 4-6 D).  Env- controls were used in 
this assay for each variant used, and generally exhibited an 8-fold decrease in 
virus capture by MDDCs (results not shown). 
4-7 The effect of α4β7-integrin expression on CD4+ T-cells: 
  Recently, there has been a focus on the potential importance of α4β7-
integrin in the establishment of HIV-1 infection and the initial steps involved in 
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transmission.  The α4β7 integrin has been shown to play a role in gut-homing for 
CD4+ T-cells [178, 179], as well as localizing on the cell surface with both CD4 
and CCR5 [180], and is known to be present in abundance in the genital mucosa 
on CD4+ T-cells [181].  α4β7 interacts directly with HIV-1 gp120 via a conserved 
LDV motif found in the V2 loop [182].  Taken together, this implies there may be 
a significant role for α4β7 and its interaction with gp120 in determining which 
HIV-1 variants are preferentially spread across the genital mucosa and the gut 
wall.  The distinct conformation of mac tropic and non-mac tropic Envs, in 
addition to their differing interactions with CD4, could lead to divergent 
requirements for their interactions with α4β7.  First, using Jurkat cells, a leukemic 
T-cell line [183], which express CD4, CCR5, CXCR4, α4, and are either β7+ or 
β7-, these cells were infected by the macrophage tropic and non-macrophage 
tropic Env+ GFP reporter pseudovirions using the envs detailed in table 4.1.  The 
macrophage tropic Envs infected both α4β7+ and α4β7- Jurkat cells better than 
non-macrophage tropic Envs (Fig. 4-7).  When comparing overall infectivity of the 
α4β7+ and α4β7- cells, there was no difference between them, indicating that 
α4β7 may not play a role in Env tropism in this in vitro system.   
The Jurkat cells may not adequately represent how these Envs infect 
primary human cells.  To test this, α4β7+ and α4β7- CD4+ T-cells populations 
were isolated and infected directly with Env+ GFP-reporter pseudovirions.  Two 
days post infection, GFP positive cells were quantified.  α4β7+ and α4β7- CD4+  
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FIG. 4-7. Macrophage tropic Envs infect Jurkat cells more efficiently than non-
macrophage tropic Envs.  R5 Envs described previously were used to generate 
GFP reporter pseudovirions.  These were then titrated onto a T-cell line, Jurkat 
E6-1 cells. (A) Jurkat cells expressing CD4 and CCR5 were used to titrate 
pseudovirus. 2 days post infection, infectivity was quantified.  Mac-tropic Envs 
infected these cells more efficiently than non-mac tropic Envs.  (B) Jurkat cells 
expressing α4β7 in addition to CD4 and CCR5 were used in the same assay as 
in (A), and the same result was achieved.  (C) There is no difference in sensitivity 
between Jurkat cells that express and do not express α4β7 with the envelopes 
used in this study. P values were generated using the Mann-Whitney T-test.  
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FIG. 4-8. Infection of β7+ CD4+ T-cells by macrophage tropic and non-
macrophage tropic envs. 100µL of GFP-reporter viral supernatant titrated on β7+ 
CD4+ T-cells sorted by flow cytommetry and infectivity was quantified 2dpi.  (A) 
No significant difference was observed between macrophage tropic and non-
macrophage tropic envs on β7- CD4+ T-cells.  The four transmitted-founder envs 
used infected the sorted cells efficiently.  (B) β7+ CD4+ T-cells were similarly 
infected regardless of macrophage tropism.  (C) The same pattern of infectivity is 
observed on β7- and β7+ CD4+ T-cells between mac and non-mac tropic envs, 
although β7+ cells were more susceptible to infection.  Data presented here is 
from a single experiment, representative of several conducted.  P values were 
generated using the Mann-Whitney T-test.   
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T-cells were both efficiently infected by both mac and non-mac tropic envelopes 
(Fig. 4-8 A-B), and no significant difference is seen with respect to macrophage 
tropism.  Mac-tropic Envs confer higher infection on CD4+ T-cells compared to 
non-mac tropic Envs regardless of the presence of the integrin α4β7 (Fig. 4-8 C).  
Overall, β7+ cells were more susceptible to infection than β7- cells (Fig. 4-8 C), 
as has been reported previously [180].  
4-8 The innate immune response of MDDCs does not affect trans infection of 
CD4+ T-cells by non-mac tropic Envs 
  Non-macrophage tropic R5 envelopes are frequently predominant in 
immune tissue late in disease [91, 98, 108].  However the data presented here 
do not show that they carry a replicative advantage for CD4+ T-cells.  It has been 
suggested that HIV-1 avoids infection of mDCs so as to not induce an innate 
immune response, such as type I interferon release.  Here, it was evaluated 
whether highly mac-tropic envelopes induced type I interferon production 
following infection of MDDCs.  MDDCs are readily infected, whether they are 
mature or immature, by highly mac-tropic Env+ pseudovirions.  Pseudovirions do 
not produce a viable infection (they do not code for Env and carry T-cell line 
adapted HIV-1 genes), and they may interact with the DC in a different manner 
from replication competent viruses, potentially stimulating different innate 
immune responses.  In the context of an in vivo infection, the DCs may also 
generate a significant immune response that may affect their ability to transmit 
virus to other target cells.  To address this, replication competent virus was used  
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FIG. 4-9. Infection of MDDCs with replication competent virus does not induce 
IFN production. Replication competent full-length molecular clones were 
pseudotyped with VSV-G, and used to directly infect MDDCs.  The supernatant 
from these infected MDDCs was measured by ELISA for IFNα.  (A) On the left 
are MDDCs infected with VSV-G AD8 and on the right are mock-infected 
MDDCs.  Both were immunostained for p24.  (B) The supernatant from these 
infected MDDCs was measured by ELISA for IFNα, 4 days post infection.  AD8 
and YU2 supernatants were at the very bottom of the limit of detection, while 
JRCSF and NL4.3 supernatants had no detectable IFNα.  Data shown are from a 
single experiment representative of several. 
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to directly infect MDDCs.  These full-length molecular clones were also 
pseudotyped with VSV-G protein in order to facilitate maximum virus entry.  Four 
days post infection, cellular supernatant was used from these infected MDDCs to 
measure type I IFN.  There was virtually no type I IFN response in the infected 
MDDCs (Fig. 4-9).   
4-9 DISCUSSION: 
 Non mac-tropic R5 viruses predominate in immune tissue, even in late 
stage disease of HAD subjects, when highly mac-tropic variants can be found in 
the brain [108].  These non-mac tropic viruses must have some advantage that 
allows them to predominate in immune tissue, or conversely there may be a 
disadvantage to mac-tropic viruses in immune tissue.  In the in vitro experiments 
conducted here with mac-tropic and non-mac tropic Envs, the mac-tropic Envs 
directly infected DCs and CD4+ T-cells better than the non-mac tropic Envs, and 
are at least equivalent when trans-infected via MDDCs.  I also evaluated whether 
or not the integrin α4β7 conferred an advantage for non-mac tropic Envs.  
Although β7+ cells were more susceptible to infection than β7-, there was no 
advantage for non-mac tropic viruses using this integrin.  In fact, none of these 
assays demonstrated an advantage for non-mac tropic Envs.  Yet mac-tropic 
virus does not seem to predominate in immune tissue throughout the majority of 
infection, nor is it preferentially transmitted.  Given that these experiments 
demonstrate that macrophage tropic Envs facilitate more efficient infection of 
dendritic cells, it is possible that they may stimulate a greater immune response, 
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acting to curtail their replication in CD4+ T-cells.  At least for type I interferon, this 
does not appear to be the case. 
 It has been shown before that dendritic cells can be infected by HIV-1, and 
that immature DCs were significantly more susceptible to infection than mature 
DCs [123, 169].  The immature MDDCs used in this study were susceptible to 
infection, but only by R5 Envs, similar to what has been observed previously with 
macrophages [91, 97, 98, 168].  The isolate most often used in DC infection 
assays reported previously was BaL [121, 184], which is known to be a highly 
mac-tropic Env.  The non-mac tropic R5 Envs tested here most likely were 
unable to utilize the low CD4 levels of these MDDCs, indicating that the term 
macrophage tropism can also refer to dendritic cells.  The DCs were significantly 
less susceptible to infection than were macrophages, possibly due to the post-
entry restriction of SAMHD1 and APOBEC3A [73, 74, 185], which were not 
alleviated in these assays.   
Mature dendritic cells have been generally regarded as refractory to 
infection with HIV-1, but here they were as susceptible to infection by mac-tropic 
strains as are immature MDDCs.  During the course of HIV infection, increased 
bacterial translocation across the intestinal lumen occurs, thereby increasing 
plasma LPS levels [186].  This can potentially cause systemic activation of DCs, 
which might indicate that HIV-1 has a greater chance of interacting with mature 
DCs over the course of infection than immature DCs.  A previous study 
demonstrated that mature DCs were more resistant to viral fusion [187], however 
84
this study utilized lab adapted virus.  Had mac-tropic primary isolated virus been 
used, the ability to exploit the very low levels of receptor and co-receptor may 
have overcame this fusion resistance.     
 In addition to infecting DCs, mac-tropic Envs are able to infect CD4+ T-
cells very efficiently.  Previously, CXCR4 tropic viruses were described as T-
tropic viruses, until it was shown that CCR5 using viruses can readily infect these 
cells [87, 88].  The non-mac tropic Envs infect CD4+ T-cells efficiently, which is 
expected since these were derived from immune tissue, where CD4+ T-cells are 
major targets for infection.  The mac-tropic Envs are derived from mostly neural 
sites and are adapted to utilize the low levels of CD4 found on myeloid cells.  
CD4+ T-cells express significantly higher levels of CD4 on the cellular surface 
than do macrophages or dendritic cells, which might explain why they are more 
efficiently infected by these mac-tropic isolates that use CD4 more proficiently 
than non-mac tropic isolates.  
Mac-tropic Envs infected CD4+ T-cells more efficiently than non-mac 
tropic Envs, however in the context of a trans-infection, both types of Envs 
infected CD4+ T-cells similarly.  Trans infection of CD4+ T-cells facilitated by 
DCs has been described, stemming from the transfer of virions internalized by 
the DC [177].  These mac tropic Envs interact more efficiently with CD4, which 
could act to either bind the virus to the DC more efficiently or more effectively 
present the virus at the site of infectious synapse formation.  However, this 
interaction with CD4 by mac tropic viruses did not result in more virus particles 
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(measured by p24) being captured (Fig. 4-6 D), consistent with alternative 
mechanisms of HIV-1 attachment, such as DC-SIGN and others [188, 189].  
Recently, it has been suggested that a subset of CD4+ T-cells expressing 
the integrin α4β7 could play an important role in HIV-1 infections.  Mac-tropic 
Envs infected this subset of T-cells more efficiently than non-mac tropic Envs, 
which was no different from CD4+ T-cells unsorted for α4β7 expression.  Overall, 
the α4β7+ T-cell subset was more efficiently infected, which is in accordance 
with previous findings [180], regardless of macrophage tropism.  The 
determinants for gp120 interaction with α4β7 may not be related to determinants 
for macrophage tropism.  In light of recent findings regarding the role of 
transmitted founder variants and α4β7 [190], several non-mac tropic T/F Envs 
were used to infect α4β7+ CD4+ T-cells, and exhibited the same infectivity 
pattern as the other mac and non-mac Envs used.  Overall, this data suggests 
that interaction of gp120 with α4β7 is distinct from macrophage tropism.   
In light of macrophage tropic isolates ability to exploit the low levels of 
CD4 on DCs for infection, these mac-tropic Envs may stimulate a greater innate 
immune response than non-mac-tropic Envs.  Using replication competent, 
VSVG-pseudotyped virus, virtually no type-I IFN response was generated by 
infected MDDCs.  A very slight response can be detected in the case of mac-
tropic viruses, but most likely does not account for the ability of non-macrophage 
tropic virus to persist in immune tissue during the course of disease progression.    
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In summary, macrophage tropic Envs are able to facilitate infection of both 
mature and immature MDDCs, due to their ability to exploit low levels of CD4 for 
infection.  CD4+ T-cells are also more efficiently infected by mac tropic 
envelopes, most likely due to their efficient interaction with CD4 as well, without 
preferential use of α4β7. Together, these data show that mac tropic Envs confer 
more efficient (or equivalent) infection of all CD4+ cell types tested.  The 
predominance of non-mac tropic R5 Envs in immune tissue is therefore not due 
to an enhanced tropism for DCs or CD4+ T-cells present there.        
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CHAPTER V: DISCUSSION 
5-1 Summary of Results: 
 My data demonstrate that a conserved determinant in the V1 loop of 
gp120 can modulate macrophage tropism.  Making the glutamate to glycine 
change at position 153 can impart the ability to utilize low levels of CD4 for 
infection and macrophage tropism.  This change can also cause an enhanced 
sensitivity to the V3 mAb 447-52D, as well as sCD4.  Taken together, these data 
indicate that E153G causes a shift in the position of the V3 loop that in turn 
facilitates an enhanced ability to undergo conformational changes upon 
interacting with CD4.  This greater propensity or flexibility for undergoing the 
conformational change to the CD4-bound form of gp120 enables these 
envelopes to utilize the low levels of CD4 on macrophages for infection.  
 The ability to utilize low levels of CD4 for infection of macrophages was 
also shown here to expand to mDCs, regardless of their maturation state.  
Macrophage tropism extends to other myeloid lineage cells, while non-
macrophage tropic Envs do not have an increased tropism for CD4+ T-cells 
compared to mac-tropic Envs.  Non-macrophage tropic Envs, largely isolated 
from immune tissue, infect CD4+ T-cells directly less efficiently than mac-tropic 
Envs.  MDDCs transmission to CD4+ T-cells occurs irrespective of the degree of 
macrophage tropism, demonstrated by the transmission experiments presented 
here.  Jurkat cells and CD4+ T-cells expressing α4β7 are more permissive to 
infection, but macrophage tropism does not affect the interaction of gp120 with 
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α4β7.  Lastly, mac-topic viruses do not stimulate a significant innate immune 
response via DCs.  Taken together, these data indicate there is no significant 
beneficial advantage to non-mac tropic Envs over mac-tropic Envs with respect 
to CD4+ T-cell infectivity and innate immune stimulation.   
5-2 Residue 153 and Tropism: 
 Determinants have been identified for R5 macrophage tropism in a 
number of regions of gp120 [98, 104, 105], but not before in the V1 loop.  It is 
striking that in several heterologous envs residue 153 is able to drastically alter 
sensitivity to a V3-loop antibody and sCD4, as well as the ability to exploit low 
levels of CD4 for infection.  From a structural perspective, this makes sense in 
light of recent structural determinations of the V1/V2 loops [48].  Several studies 
indicate that V1/V2 shields and interacts with V3 [151, 191].  The presence of a 
charged residue, specifically a glutamate, at position 153, the base of the V1 
loop, may more stably shield the V3 loop by facilitating a polar interaction, 
whereas a glycine may allow greater mobility of the V1 loop.  This greater 
mobility and weaker interaction with V3 would explain the greater neutralization 
sensitivity to 447-52D, as well as a greater sensitivity to sCD4.  Changes 
resulting from mutation at position 153 are very focused and specific, indicating 
that a major structural change is not occurring in the context of the trimer.  
Further analysis of this V1/V2-V3 loop interaction may help to show what 
conformational changes occur following CD4 binding.   
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Understanding the interrelationship between V1/V2, V3, and CD4 binding 
will contribute to a greater understanding of how to target this site to prevent 
binding and to develop effective vaccines to the CD4 binding site.  In light of 
recent data stemming from the RV144 vaccine trial, indicating a correlation with 
V1/V2 antibodies and protection, understanding the structural implications of 
residue 153 may contribute to better antigen design [192].  The V1/V2 epitope 
may be significantly important in contributing to the adaptive immune response to 
HIV-1, especially if the interaction of V1/V2 with V3 affects how gp120 interacts 
with CD4.  Macrophage tropic envelopes may be generally more susceptible to 
neutralization or inhibition by V1 and V3 directed antibodies, which could 
certainly help explain why they are not found in immune tissue during the course 
of disease progression.  If non-mac tropic Envs are more resistant to V1 and V3 
antibodies, then these Envs should be utilized as antigenic models for the 
development of antibodies and small molecule inhibitors.      
These data show a potential interaction between V1/V2 and V3.  This 
interaction may result in altered interaction with the co-receptors for HIV-1, CCR5 
and CXCR4, due to theV3 loop being the deterministic site of co-receptor binding 
[193].  Although no significant change in sensitivity to maraviroc was observed 
(Table 3-2), this alone may not explain altered co-receptor interaction since 
maraviroc is a small molecule inhibitor directed towards CCR5 usage that binds 
CCR5 to inhibit its interaction with gp120 [194].  Inhibitors directed towards the 
sites of CCR5 and gp120 interaction may better elucidate how macrophage 
90
tropism affects CCR5 usage.  A higher sensitivity to V3 loop antibodies by mac 
tropic Envs may correlate to a greater exposure of the V3 loop in these Envs.  
The experiments presented here may help support experiments that suggest 
mac tropic Envs are better able to utilize low levels of CCR5 [111], or even 
CXCR4.  This may be contributed to through a mechanism whereby the charge 
or structure of V1 affects co-receptor interaction with gp120 through V3.      
5-3 Mac-tropic and Non-Mac tropic envelopes and tropism: 
Non-mac tropic Envs predominate in immune tissue throughout infection, 
yet the data presented here demonstrate they do not have any advantage 
infecting CD4+ T-cells.  Their predominance in immune tissue may stem from 
their inability to utilize low levels of CD4 for infection.  This trait may translate to a 
decreased sensitivity to CD4bs antibodies, leading to less neutralization and 
antibody-dependent cell-mediated cytotoxicity and viral inhibition (ADCC and 
ADCVI) than mac tropic Envs.  CD4bs antibodies are known to be present in the 
host at all stages of infection [195, 196], and although they may not be present in 
large quantities, they are most likely constantly exerting selective pressure on 
viral quasi-species, particularly those present in immune tissue [197].  The 
greater sensitivity to CD4bs antibodies of mac-tropic Envs may explain their 
apparent relegation to more immune privileged sites.  Despite being capable of 
more efficiently infecting CD4+ target cells, this increased efficiency may result in 
greater stimulation of ADCC and ADCVI.  While there doesn’t appear to be any 
difference between the level of immune activation of the mac-tropic and non-mac 
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tropic viruses, it may not be immune activation that distinguishes between these 
two types of virus, but immune detection. 
Dendritic cells are susceptible to macrophage tropic viruses in these 
experiments.  Interestingly, despite not alleviating the post-entry restriction 
present in myeloid lineage cells described earlier in this thesis, efficient infection 
of these cells by mac tropic Envs is accomplished.  The specific mechanisms that 
permit this infection are not known, although there may be something specific to 
mac tropic gp120 that makes it less susceptible to this post-entry restriction by 
SAMHD1.  Further experimentation is needed to determine if there is a difference 
in the behavior of mac tropic and non-mac tropic variants post-entry.  
Additionally, upon infecting MDDCs with VSV-G pseudotyped replication 
competent HIV-1, a very minimal type I IFN response is observed.  This is 
contrary to what is seen by others after treating these MDDCs with SIV virus-like 
particles in order to introduce Vpx to alleviate SAMHD1 restriction [198].  This 
IFN response may be dependent upon Vpx, which is not a protein encoded by 
HIV-1.  The MDDCs that were treated with Vpx may stimulate an innate immune 
response because they are treated with antigens from two different pathogens, 
namely SIV and HIV-1.  This lack of an innate immune response in the HIV-1 
infected MDDCs presented herein requires further investigation to determine the 
difference in innate immune response observed.        
5-4 Future Studies: 
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 Experiments detailed here identified residue 153 in the V1 loop as 
modulating macrophage tropism.  The presence of a glutamate at position 153 is 
conserved across clades A, B, and C (Table 3-1), yet most experiments shown 
here focus on R5 clade B Envs.  Several heterologous envelopes are identified 
here that are sensitive to the E153G change with respect to macrophage tropism. 
Dementia has been studied in many cases of clade B infection, and it has been 
argued that instances of neuropathogenesis are even less severe in clade C than 
in clade B [199].  This is consistent with E153 being associated with non-mac 
tropic Envs, and potentially slower disease progression.  It was further 
determined that the presence of a glycine at position 153 was prevalent in clade 
D.  The potential link between HIV-associated dementia and macrophage tropism 
has been discussed, but in light of this potential link, it is interesting that there are 
reports of clade D being associated with higher incidences of dementia [164], as 
well as faster disease progession [159-163].  It would be interesting to determine 
if G153 is associated with neurotropic viruses across clades, as well as HIV-1 
associated neurological conditions.  G153 could be consistent with faster rates of 
disease progression and a macrophage-tropic phenotype in clade D isolates, as 
well as other clades.   
 This E153G change causes an increased sensitivity to 447-52D, a V3-loop 
antibody, as well as sCD4.  This suggests that the presence of a glycine at 
position 153 facilitates a shift in the position of the V3 loop.  This V3 loop 
conformational change may result in a more open conformation, providing 
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greater accessibility to CD4, or it may permit an easier transition from the 
unliganded structure of the trimeric glycoprotein spike to the CD4-bound 
conformation.  This change may be the result of the charge change within V1 
resulting from the absence of a glutamate.  In order to determine specifically the 
structural implications of this position, obtaining highly resolved structures of the 
trimeric glycoprotein spike in complex with 447-52D or CD4 with varying amino 
acids at postion 153 would shed light on the conformational effect position 153 
imparts, if any. 
 In addition to further exploring the effects of specific determinants, the 
effects of HIV-1 infection on mDCs and MDDCs needs further investigation.  The 
type I IFN response was evaluated here, and found to be minimally stimulated in 
the context of these experiments.  It may be the case that there are other 
cytokines or chemokines that are more relevant in the case of HIV-1 infection.  
IL-10 is a known immunoregulatory cytokine, and there have been several 
reports regarding how it is upregulated upon infection and co-culture with T-cells 
[200, 201].  It may be the case that mac-tropic envelopes elicit greater production 
of immunosuppressive cytokines due to their ability to infect MDDCs.  Utilization 
of multiplex cytokine analysis may help to shed light on the effect HIV-1 infection 
has on this.  In addition to evaluating differential innate immune response, 
evaluating the potential difference in the ability to stimulate ADCC and ADCVI 
may show that mac-tropic virus is more readily detectable and more easily 
dispatched by the humoral immune system than are non-mac tropic viruses.    
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5-5 Conclusion: 
 This thesis identifies a determinant of macrophage tropism in the V1 loop.  
This determinant appears to change the conformation of the V3 loop and 
facilitate a more efficient change when gp120 encounters CD4.  Understanding 
how the V1/V2 and the V3 loop contribute to the accessibility of the CD4 binding 
site will greatly contribute to antigen and vaccine design.  The role of 
macrophage tropic virus in the context of infection is still unclear.  Non-
macrophage tropic virus persists throughout the course of infection, and appears 
to be preferentially transmitted; yet it does not seem to have a distinct advantage 
for infecting distinct cell types.  Overall, understanding macrophage tropism, from 
the level of determinants to its role in pathogenesis, may contribute to the 
development of novel therapeutics.        
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